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2. SUMMARY 
Coronary artery disease (CAD) in dyslipidemic and diabetic subjects remains the 
leading cause of death in the Western society. Current therapeutic strategies to prevent 
cardiovascular diseases are primarily based on the use of statins, which inhibit key 
enzyme in the cholesterol synthesis, HMG-CoA reductase. Another prominent risk factor 
for developing premature atherosclerosis is the low levels of high-density lipoprotein 
cholesterol (HDL-C). Despite documented benefits of statins a good proportion of 
individuals still remain at a higher risk of developing CAD. Therefore, focus has shifted 
on HDL-raising therapeutics to further improve the CV outcome. While Niacin and 
fenofibrate have not shown clinical benefits in two separate trials, results from CETP 
inhibitors, Torcetrapib and Dalcetrapib, in phase 3 clinical studies have been 
disappointing despite substantial increase in HDL-C. One of the challenges encountered 
with measuring plasma HDL as a biomarker for cardiovascular risk is the fact that the 
antiinflammatory HDL becomes pro-inflammatory after it undergoes oxidative 
modification in diabetics. Pro-inflammatory states have also been shown to reduce HDL 
functionality. Thus, the lack of translatability of animal results to humans has further 
added challenges in the HDL therapeutics area. These findings necessitated rethinking 
about HDL therapeutics leading to transition in HDL therapy concept that seems to focus 
more around HDL functionality rather than HDL level. This PhD dissertation focuses on 
factors that influence HDL functionality and analyzes a correlation between HDL 
functionality and aortic lipid deposition. Several agents that raise HDL levels have been 
utilized to dissect HDL functionality. In addition, animal model of diabetes and 
atherosclerosis was employed to establish a correlation between HDL functionality, 
hyperglycemia and inflammation. Through a series of studies, it is shown that HDL 
function correlates with beneficial effects, and diabetes and inflammation dampens HDL 
functionality leading to increased accumulation of aortic lesion formation. Agents that 
attenuate hyperlipidemia, glycemic index and proinflammatory state improved HDL 
functionality leading to reductions in atherosclerotic burden.  
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3. HYPOTHESES 
Despite the well-documented benefits of statin treatment, cardiovascular disease 
remains a major risk factor for developing coronary artery disease. To further impact the 
CV outcome, efforts have been made towards HDL-raising therapeutics, including niacin 
and PPAR-α activators. However, clinical benefits of these therapies remain uncertain 
because of the failure of CETP inhibitors, Torcetrapib and Dalcetrapib, in phase 3 clinical 
trials. Low levels of HDL remain a prominent risk factor for developing premature 
atherosclerosis in diabetics. It is therefore hypothesized that: 
a) HDL functionality, not the HDL level, is important in removing cholesterol 
from periphery by a process called reverse cholesterol transport 
b) HDL functionality correlates with extent of aortic lipid deposition 
c) HDL functionality is compromized in animal models of hyperlipidemia, 
oxidative stress and hyperglycemia 
d) Proinflammatory state modifies HDL functionality 
e) Attenuation of insulin resistance, hyperglycemia, and inflammation restores 
HDL functionality and promotes plaque regression. 
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4. APPROACH 
The above hypotheses were tested in established and widely used animal models 
using available tool molecules shown to influence RCT in animal models. The 
hypotheses were tested in the following steps: 
a) Since ABCA1 is the most important player in the maturation of HDL and 
promotion of cellular cholesterol efflux, a stable cell line was developed to 
evaluate direct correlation between ABCA1 expression and cholesterol efflux to 
show that ABCA1 deinduction abolishes cholesterol efflux 
b) Optimization of in vivo cholesterol efflux in C57Bl mice using both 
radioisotopic and nonradioisotopic method 
c) Evaluation of ABCA1 inducers on cholesterol efflux in Rader’s assay 
d) Demonstration of HDL functionality and RCT pathway gene induction in WT 
and genetically altered mouse models 
e) Investigation of HDL functionality in animal models of diabetes, 
hyperlipidemia and atherosclerosis. 
f) Demonstration of inverse correlation between HDL functionality and aortic 
lipid deposition. 
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5. ABBREVIATIONS 
ABBREVIATION DEFINITION 
  
ABCA1 ATP-binding cassette transporter A1 
ABCG1 ATP-binding cassette transporter G1 
ABCG5 ATP-binding cassette transporter G5 
Apo Apolipoprotein 
ApoA-I Apolipoprotein A-I 
AMPK Adenosine monophoasphate kinase 
ApoB Apolipoprotein B 
AUC Area under the curve 
BHK Baby hamster kidney 
b.i.d. Twice daily dose 
8-Br-cAMP 8-bromo cyclic adenosine monophosphate 
CAD Coronary artery disease 
cAMP Cyclic AMP 
CE Cholesterol ester 
CETP Cholesterol ester transfer protein 
ChreBP Carbohydrate response element binding protein 
CRE-BP Cyclic AMP response element binding protein 
COE Cholestery oleyl ester 
CRP C-reactive protein 
Cyp7A1 Cholesterol 7-alpha hydroxylase 
CV Cardiovascular 
CVD Cardiovascular disease 
Chol Cholesterol 
CMC Carboxymethylcellulose 
DKO Double knockout 
DMSO Dimethylsulfoxide 
FAS Fatty acid synthase 
FC Free cholesterol 
FPLC Fast protein liquid chromatography 
FXR Farnexoid X receptot 
g, gm Gram(s) 
h, hr Hour(s) 
HAEC Human aortic endothelial cell 
HCl Hydrochloric acid 
HDL High-density lipoprotein 
HDL-C High-density lipoprotein cholesterol 
HPLC High performance liquid chromatography 
HMGCoA Hydroxymethyl glutarate CoA 
IACUC Institutional animal care and use committee 
 
 
11 
IL-1β Interleukin 1-β 
IL-6 Interleukin-6 
IFN-γ Interferon-gamma 
IMT Intima media thickness 
kg Kilogram(s) 
LDL Low-density lipoprotein 
LDL-C Low-density lipoprotein cholesterol 
LDLr Low-density lipoprotein receptor 
LPS Lipopolysaccharide 
LUV Large unilamellar vesicles 
LXR Liver X- receptor  
MCH Mean corpuscular hemoglobin 
MCP-1 Macrophage chemo-attractant protein 1 
MetS Metabolic syndrome 
MIP1b Macrophage inflammatory protein 1b 
mg Milligram(s) 
mRNA Messenger RNA 
mL Milliliter(s) 
MPO Myloperoxidase 
MS-RCT Macrophage-specific reverse cholesterol transport 
MS Metabolic syndrome 
MUV Medium unilamellar vesicles 
N Number  
ND Not determined 
PBS Phosphate-buffered saline 
PD Pharmacodynamics 
PK Pharmacokinetics 
PL Phospholipids 
PO Oral dosing 
PPAR Peroxisome proliferator-activated receptor 
rHDL Reconstituted HDL 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT-PCR Reverse transcriptase- polymerase chain reaction 
RXR  Retinoid X-receptor 
SAA Serum Amyloid A 
SD Standard deviation 
SEM Standard error of the mean 
SAA Serum amyloid 
SCD1 Steroyl CoA desaturase 
SHP Small heterodimer parner 
SR-B1 Sacvenger receptor class B type I 
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SREBP1c Sterol response element binding protein 1c 
SREBP2 Sterol response element binding protein 2 
SUV Small unilamellar vesicles 
TC Total cholesterol 
TD Tangier’s disease 
Tg Transgenic 
TG Triglycerides 
TLR Toll-like receptor 
TNF-α Tumor necrosis factor- α 
µg Microgram(s) 
µL Microliter(s) 
µM Micromolar 
UTR Untranslated region 
USF1 Upstream stimulatory factor1 
VCAM-1 Vascular adhesion molecule-1 
VLDL-C Very low-density lipoprtoein 
WK Week 
WHAM Wisconsin Hypoalpha Mutant 
XBP1 X-box binding protein 1 
ZNF202  Zinc finger protein nuclear factor 
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6. INTRODUCTION 
6.1 Cardiovascular Disease and HDL-C 
Coronary artery disease (CAD) remains the leading cause of death in the United 
States and other developed countries (1). While elevated levels of low-density lipoprotein 
cholesterol (LDL-C) and triglycerides are risk factors for developing coronary artery 
disease (2), a pathological hallmark of atherosclerosis is the excessive accumulation of 
cholesterol by macrophages, leading to their conversion to foam cells (3,4). Since LDL-C 
has been linked to CAD, current therapeutic strategies to prevent atherosclerosis are 
primarily based on the use of statins, which inhibit HMG-CoA reductase, a key enzyme 
in the de-novo cholesterol synthesis, and thereby leading to decreased serum LDL-C 
(2,5,6). Another prominent risk factor for developing premature atherosclerosis is the low 
levels of high-density lipoprotein cholesterol (HDL-C) (7). Despite documented benefits 
of statins (2), a good proportion of individuals still remain at a higher risk of developing 
CAD (8). HDL-C levels are inversely correlated with the risk of coronary artery diseases 
(8-11) as evidenced by clinical trial results (12-14). There has been a marked increase in 
the disease risk factor referred to as Metabolic Syndrome (MS) and characterized by a 
clustering of risk factors leading to developing cardiovascular diseases (15-17). Low 
HDL-C is characterized as one of the features of MS. The other risk factors include 
dyslipidemia, hypertriglyceridemia, hypertension, and impaired glucose tolerance. A 
recent report suggests that MS is becoming pandemic and the number of individuals 
suffering from MS is likely to double by 2030 worldwide (18). Therefore, aiming to 
correct dyslipidemia and increase HDL-C may reduce the risks of developing 
atherosclerotic lesion formation. Low HDL-C levels are the most common lipid 
abnormalities observed in men with CAD (11). ApoA-I, the major protein component of 
HDL, determines the blood levels of HDL-C (19) and promotes cholesterol efflux, which 
in turn promotes reverse cholesterol transport. Therefore, elevating HDL-C may have 
protective effects on the development of CAD. The current hypothesis of HDL’s 
protective role depicts that HDL inhibits atherogenesis by promoting cholesterol efflux 
from peripheral tissues and from lipid-laden macrophages and smooth muscle cells. HDL 
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is suggested to inhibit atherogenesis through other pathways where it exerts direct effect 
on the vessel wall, and inhibits lipoprotein oxidation. The most important 
atheroprotective function, however, is the HDL-mediated enhancement of reverse 
cholesterol transport, a process in which HDL receives excess cholesterol from the 
peripheral tissues, including macrophages in the arterial wall, which is subsequently 
delivered to the liver for biliary excretion. The understanding of reverse cholesterol 
transport and the molecular mechanisms that control serum HDL cholesterol levels have 
been dramatically increased by the discovery of scavenger receptor- BI (SR-BI) (20,21), 
ATP-binding cassette transporter A1 (ABCA1) (22,23), and ATP-binding cassette 
transporter G1 (ABCG1) (24). 
6.2. HDL Pathway and Reverse Cholesterol Transport 
Cholesterol is transported as two main lipoprotein particles in our body. One is 
the low density lipoproteins (LDL) or the ‘bad cholesterol’ synthesized and secreted by 
the liver, and subsequently cholesterol in LDL particles are taken to the peripheral tissues 
for cellular needs, and the other is HDL or ‘good cholesterol’ that brings back cholesterol 
from the peripheral tissues to the liver for excretion as bile. The main protein component 
of the LDL particle is the apolipoprotein B, a 550 kDa ampipathic protein, which serves 
as a ligand for the LDL receptor-mediated uptake by various tissues (25,26). The main 
protein component of HDL particles is the apolipoprotein A-I (27-29). Several metabolic 
pathways determine the net concentration of the HDL in the circulation. As depicted in 
Fig. 1, HDL particles are synthesized and secreted by the liver and intestine. The HDL 
precursors, also called as nascent HDL or HDL discs, are generated through the action of 
lipoprotein lipase on chylomicrons and very low-density lipoproteins as well as by the 
direct secretion by the liver. In the plasma, HDL undergoes structural and compositional 
changes by the action of lipid transfer proteins and lipases, and by the exchange of 
apolipoproteins and lipids between circulating lipoprotein particles. HDL particles bring 
back cholesterol from the peripheral tissues to the liver for excretion (Fig. 2). Scavenger 
receptor class B type I (SR-B1) (21) and cubulin and megalin (30) have been suggested 
to be involved in the uptake of HDL particles. Thus, plasma levels of HDL represent a 
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net result of the rates of production into and the rates of clearance from plasma. Reverse 
cholesterol transport refers to the process by which cholesterol is removed from the 
tissues and returned to the liver. HDL is the key lipoprotein involved in reverse 
cholesterol transport and the transfer of cholesteryl esters between lipoproteins. The 
smallest and most dense lipoprotein particle is HDL, which undergoes maturation when 
precursor particles (nascent HDL), secreted by the liver and intestine, proceed through a 
series of conversions (known as the "HDL cycle") to attract cholesterol from cell 
membranes and free cholesterol to the core of the HDL particle. The action of cholesteryl 
ester transfer protein (31), which transforms HDL into a TG-rich particle that interacts 
with hepatic-triglyceride lipase. Cholesterol ester-rich HDL may also be taken up directly 
by the receptors in the liver. Another mechanism may be that cholesterol esters are 
delivered directly to the liver for uptake without catabolism of the HDL cholesterol 
particle (21).              
  
Fig. 1. A general scheme showing metabolic pathways regulating plasma levels of HDL. As shown, 
plasma levels of HDL are controlled by its rates of production into and the rates of removal from 
plasma. Production rates of HDL, as depicted, are determined mainly by the production rates of 
apoA-I, while the removal of HDL from plasma is regulated by structural and compositional 
changes of circulating HDL particles as well as receptor-mediated uptake by the liver and other 
peripheral tissues.                                             
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Among other players, SR-BI (21), ABCA1 (23), and hepatic lipase (32) appear to 
be important in the reverse cholesterol pathway. In ultracentrifugation, HDL floats at a 
density of 1.09–1.21, g/ml. HDL particles can also be separated by their size using gel 
permeation chromatography that separates particles based on their size (25,27). Since 
VLDL and LDL particles are larger than HDL, these particles elute from the FPLC 
column in the order of: VLDL, LDL, and HDL. HDL particle sizes range in diameter 
between 70 and 100 Å and their molecular mass ranges from 200–400 × 103 daltons (25). 
The concentrations of plasma HDL are expressed by their cholesterol content, although 
the cholesterol content of the HDL particles is only about 15%. HDL circulates in plasma 
as spherical particles. Cholesteryl esters form the ‘core-lipid’, and depending upon the 
action of lipid transfer proteins, variable amounts of triglycerides are present in the HDL 
particles. The outer surface of the HDL particle contains free cholesterol, phospholipids, 
and apolipoproteins. In human plasma, the presence of several discrete classes of HDL 
sub-populations has been identified. These HDL subclasses vary in their size, and 
composition. HDL2 and HDL3 are the major HDL subpopulations present in plasma of 
most animal species. HDL2 is about 50% larger than HDL3 with 3-4-fold more 
cholesteryl esters and 2-fold more phospholipids than HDL3. Several other discrete HDL 
subclasses have been identified in human plasma including HDL1, which can be 
separated from other HDL sub-fractions. Majority of the plasma apolipoprotein E in rats 
and mice are associated with HDL1. A number of apolipoproteins are associated with 
HDL. They are apolipoprotein AI, constituting 70% of the total protein in HDL particles, 
apoA-II, apoA-IV, apoE, apoC-I, C-II, and C-III. HDL particles also carry other proteins 
like LCAT, lecithin cholesterol acyltransferase (33). Throughout their circulating 
lifetime, the apoA-I molecules appear to be released and transferred between HDL 
particles by replacement of apoA-I molecule. Both apoA-I and A-II have been shown to 
exchange between HDL2 and HDL3 (34). ApoA-I and apoA-II can also exchange from 
free solution by replacing apoA-I and A-II molecules on the HDL particles. However, it 
is not possible to exchange all the apoA-I molecules on the HDL particles. Other 
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apoproteins can replace apoA-I from the HDL particles, the most important among those 
being apoA-II and apoCs (35). 
                                         
Fig. 2.  Cholesterol transport. Apolipoprotein A-I, synthesized from the liver and the gut, forms nascent 
HDL particles. The nascent discoidal HDL particle accepts cholesterol and phospholipids from the 
peripheral tissues in ABCA1-dependent manner, and gets converted into cholesteryl ester-rich 
mature HDL particles. The mature HDL particles are then taken to the liver in a process called 
reverse cholesterol transport in which SR-B1 plays an important role in docking and accepting the 
cholesterol esters from HDL particles. The cholesterols delivered to the liver is converted into bile 
by cholesterol 7-α hydroxylase and excreted to the gut.  
6.2.1. ApoA-I and Coronary Artery Disease 
ApoA-I is the major protein component of HDL and shows a strong correlation 
with the plasma levels of HDL (36,37). Human mature apoA-I consists of 243 aa with a 
molecular size of 28-kDa. It is synthesized as a precursor protein, preproapoA-I, of 267 
aa. The major sites of apoAI synthesis are the liver and the small intestine (19). Several 
studies suggest that apoA-I protect against developing premature atherosclerosis, and acts 
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as an antiatherogenic agent. Feeding high fat high cholesterol diet to African green 
monkeys resulted modest hypercholesterolemia and less atherosclerosis as comparedto 
cynomolgus monkeys, which was attributed to the higher basal levels of HDL and apoA-I 
in African green monkeys compared to cynomolgus monkeys (38). African green 
monkeys showed more than two fold circulating plasma HDL levels compared to 
cynomolgus monkeys. Measurements of apoA-I synthesis in the liver perfusates 
correlated with the plasma levels of HDL (Fig. 1). Subsequently, these authors found that 
the lower rates of apoA-I synthesis in cynomolgus monkeys were due to low levels of 
hepatic and intestinal apoA-I mRNA, suggesting that apoAI mRNA and apoA-I 
production rates determine the plasma levels of apoA-I, and hence plasma levels of HDL. 
This study suggested that higher plasma levels of HDL due to higher production rates of 
apoA-I protects against diet-induced atherosclerosis. Similar results with regard to the 
protective effects of HDL and apoA-I have been obtained in several mutant mouse 
models of atherosclerosis.  
Transgenic mouse lines over expressing human apoA-I have been developed by 
several groups (39). These apoA-I transgenic mice have higher levels of human apoA-I, 
but showed reductions in plasma levels of mouse apoA-I, and appearance of discrete sub-
populations of HDL particles (39,40). Since mouse apoA-I mRNA did not change in 
these transgenic mouse lines expressing human apoA-I, it was concluded that the over-
expression of human apoA-I possibly displaced mouse apoAI from the HDL particles, 
resulting the appearance of two subclasses of HDL populations (39). Another group of 
researchers that developed apoA-I transgenic mouse line reported increased plasma levels 
of high-density lipoproteins as a result of over-expression of human apoA-I, but the HDL 
particle sizes were smaller as compared to human HDL3 (40). They further reported that 
the alteration in the HDL particle size distribution affected selective uptake of HDL 
cholesteryl esters (40). Since higher levels of HDL and its major apoprotein component, 
apoA-I, have been implicated in lowering the risk of premature coronary artery disease, it 
is safe to hypothesize that mice over-expressing apoA-I, and secreting high levels of 
HDL should be protected from developing high fat diet-induced premature 
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atherosclerotic lesion formation. This hypothesis was tested in the apoA-I transgenic 
mice-fed high fat diet. As compared to their nontransgenic littermates, the transgenic 
mice inhibited high fat diet-induced early atherogenic fatty streak formation (41), 
confirming the antiatherogenic properties of apoA-I. The role of apoA-I and HDL in 
atherosclerosis risk was also studied in mice over-expressing human apoB and lacking 
apoA-I (42). Feeding these mice Western-type high fat diet developed lesion formation 
twice as much in mice over-expressing human apoB gene and lacking apoA-I than in 
mice over-expressing human apoB gene. These observations were further supported by 
studies carried out in the apoE-deficient mouse (43). Thus, these findings confirm the 
role of apoA-I in reducing the atheroslcerotic lesion formation, and hence the risk of 
developing premature atherosclerosis. The over-expression of apo[a] promotes lesion 
formation, while over-expression of human apoA-I in apo[a] transgenic mice lowered the 
risk of atherosclerosis by 20-fold (44). Thus, HDL is associated with the decreased 
atherosclerosis risk, and plasma apoA-I level is a major determinant of HDL 
concentrations. The role of apoA-I as an antiatherogenic agent has been established in 
animal models (43,45,46) as well as in humans (47). 
6.2.2. Cholesterol Efflux, ABCA1 and Atherosclerosis 
Bailey (48) first observed in 1965 in an in vitro model that cholesterol can be 
removed from the cells by exposing them to serum. Subsequently, Glomset 
(33)formulated the concept of ‘reverse cholesterol transport’, in which cholesterol from 
the peripheral tissues are brought to the liver by HDL particles for excretion as bile salts. 
Most of the earlier studies relating to cholesterol efflux were done on movement of 
cholesterol between serum lipoproteins and cells in a bidirectional manner. In addition to 
whole serum, several cholesterol acceptors like cyclodextrins (49), phospholipid vesicles 
such as SUV, LUV, and MUV (50), lipid-poor apolipoproteins (51,52), and reconstituted 
and native HDL (53), induced cholesterol efflux from cholesterol-loaded cells. Fournier 
et al. (54) first showed a correlation between cholesterol efflux from macrophages and 
serum apoA1 concentration, suggesting a role of apoA-I in cellular cholesterol efflux. 
Later studies in a variety of cell-types showed that other apoproteins like AII, E, and AIV 
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can also function as cholesterol acceptors (55). Smith et al. (56) as well as Sakr et al. (57) 
demonstrated that cAMP treatment of macrophages resulted in several-fold increase in 
cholesterol efflux to acceptor lipid-poor apolipoproteins. These observations together 
with other studies (51,58) suggested the existence of an interaction between the acceptor 
apolipoproteins and the cell membrane component(s). 
The assembly of apoB-containing particles is quite different compared to the 
assembly of apoA-I-containing particles. The assembly of apoB particles takes place 
intracellularly in a highly regulated manner involving several intracellular components 
that determine how much apoB particles to be assembled and secreted (26,59,60). The 
assembly of apoA-I particles, on the other hand, takes place extracellularly, in which each 
component necessary for the assembly are secreted separately and assembled in the 
circulation. That other players, in addition to those secreted by liver and intestine, are 
also involved in the assembly of HDL particles became apparent from the studies with 
WHAM chickens (61). These mutant chickens have normal secretion rates of apoA-I yet 
have only 5% of the HDL compared to normal. Later kinetic studies with labeled apoA-I 
solved this puzzle, showing that the secreted apoA-I, if not assembled into HDL particles, 
are rapidly catabolized. These studies proved to be the hall-mark in the process of HDL 
assembly, suggesting that secretion rates of apoA-I alone is not sufficient to set the 
plasma levels of HDL, as has been proposed by many investigators in the past (reviewed 
in (19) . Although the process of cellular cholesterol efflux and the roles of apoproteins in 
this process have been known for decades, it was not until 1999 when the specific role of 
ABCA1 was identified in the cellular cholesterol trafficking. Three separate groups 
simultaneously identified mutations in the Abca1 linked to TD (62-64) with incredibly 
low levels of circulating HDL, cholesterol ester storage in tissues, and susceptibility to 
premature atherosclerosis. As shown in Fig. 2, the lipid-poor apoA-I particle functions as 
a cholesterol acceptor from peripheral tissues, and gets converted into mature HDL 
particle, which then delivers this cholesterol to the liver and steroidogenic tissues via 
scavenger receptor class B type 1 (SR-B1)-mediated pathway. ABCA1 participates in the 
reverse cholesterol transport by facilitating the efflux of cholesterol from cells to the 
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acceptor lipid-poor apoA-I-particles (Fig. 2), which are then taken to the liver for 
excretion as bile salts (Fig. 1 & 2). In addition to apoA-I, other apoproteins also mediate 
cholesterol efflux by functioning as a cholesterol acceptor. The roles of various 
apolipoproteins in the ABCA1- mediated lipid efflux were recently evaluated in stably 
transfected Hela cells expressing ABCA1-GFP fusion protein (65). The apoproteins A-I, 
A-II, A-IV, C-I, C-II, C-III and E all showed more than 3-fold increase in cholesterol 
efflux compared to control cells, suggesting that other apoproteins are also capable of 
inducing cholesterol and phospholipid efflux. Thus, amphipathic helical domains appear 
to be an important feature of the acceptor molecule in the cholesterol efflux process. 
Indeed, amphipathic peptides do induce cholesterol efflux in ABCA1-dependent and 
ABCA1-independent manner. Despite other apoproteins being able to induce cholesterol 
efflux, lipid-poor apoA-I appears to be the preferred acceptor of ABCA1-mediated lipid 
efflux. Since apoA-I has been shown to specifically bind to ABCA1 (66), the lipid-poor 
apoA1 (preβ-HDL) functions as an acceptor of cholesterol and phospholipid in an 
ABCA1-dependent manner resulting the formation of mature cholesterol ester rich 
spherical α-HDL particles following the action of LCAT. SR-BI interacts with the mature 
α-HDL and facilitates the uptake of CE from the HDL particles (Fig. 2).  
ABCA1 transporters constitute a large family of proteins, and participate in the 
translocation of many different substrates across the membrane (67). The majority of 
ABC transporters are membrane proteins with two membrane domains and two ATP 
subunits, either present in one molecule (fullsize transporters) or in two polypeptide 
molecules (half-size transporters). The ABC proteins bind ATP and use the energy to 
drive the transport of various molecules across the membranes. ABCA1 is a full-size 
transporter, and one of the members of seven subfamilies having a total of 48 known 
members. ABCA1 is ubiquitously present in variety of tissue (68), notably, liver, brain, 
and steroidogenic tissues. 
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Fig. 3.  ABCA1-mediated cholesterol efflux. Lipid-poor discoidal HDL particle in the circulation accepts 
cholesterol and phospholipids from the tissues via ABCA1-mediated pathway. ABCA1 is a 
membrane protein that facilitates the transport of cholesterol and phospholipids from the tissues to 
the lipid-poor HDL particles and, as a result, the nascent HDL particles get converted into mature 
cholesterol ester-rich HDL particles capable of transporting cholesterol to the liver for excretion. 
Any defect in the membrane-associated ABCA1 protein renders them unable to mediate the 
cellular cholesterol efflux resulting into the deposition of cholesterol within the tissues. 
6.2.3. ABCA1 and HDL 
ABCA1 is a 2261 amino acid integral membrane protein. Several mutations in 
ABCA1 have been identified that cause a severe HDL deficiency syndrome, known as 
Tangier’s disease (TD) (62-64,69). The fibroblasts of these patients are unable to 
facilitate the efflux of cholesterol and phospholipids, consistent with a defective ABCA1 
in facilitating lipid trafficking across the membrane. The TD patients, among other 
abnormalities, are characterized by the accumulation of cholesteryl esters in 
reticuloendothelial cells, lipid deposits in neuronal Schwann cells, smooth muscle cells, 
and fibroblasts together with hyper-cholesterolemia and cardiovascular disease. The only 
other animal species in which functional mutation in ABCA1 gene was identified is 
Wisconsin Hypoalpha Mutant (WHAM) chicken (61). These WHAM chickens have very 
low levels of HDL due to hypercatabolism of lipid-poor apoA-I resulting in the 
accumulation of cholesteryl esters in tissues. Further insights on the role of ABCA1 were 
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gained by the development of Abca1 knockout mice by two separate groups (70,71). 
These mice lacking ABCA1 exhibited phenotypes similar to TD, and showed pronounced 
accumulation of lipids in the tissues, consistent with the reported function of ABCA1 in 
the cholesterol trafficking across the membrane. Abca1-deficient mice were severely 
hypolipidemic with almost complete absence of HDL, a condition observed in TD. 
Interestingly, the Abca1–/– mice also showed decreased absorption of cholesterol, 
suggesting a role of ABCA1 in cholesterol absorption. The loss of function of ABCA1 
and the absence of HDL in Abca1–/– was also shown to significantly affect the 
steroidogenesis (72), corroborating earlier studies that the primary source of cholesterol 
to the steroidogenic tissues is HDL via SR-B1-mediated uptake. SR-B1 is highly 
expressed in steroidogenic tissues (20).  
Recently, it was shown that ABCA1 is also involved in the trafficking of α-
tocopherol (73). Since α-tocopherol is lipid-soluble, and hence associated with 
lipoprotein particles, and since ABCA1 plays an important role in cholesterol and 
phospholipid trafficking, these authors hypothesized that ABCA1may be involved in the 
trafficking of α-tocopherol between tissues. Both in the unstimulated and in cAMP-
stimulated macrophages, α-tocopherol was found to be effluxed from the cells. Since α-
tocopherol efflux from Tangier disease fibroblast was impaired, it was concluded that 
cellular cholesterol and α-tocopherol efflux occurred via ABCA1-mediated mechanism. 
Further evidence of ABCA1-mediated α-tocopherol trafficking between tissues came 
from BHK cells transfected with ABCA1. In the transfected cells, the α-tocopherol efflux 
occurred in the presence of apoA-I, HDL, or trypsinized HDL, suggesting that ABCA1 is 
indeed involved in the trafficking of α-tocopherol. 
Since fibroblasts from TD patients and from Abca1–/– mice showed significantly 
reduced apoA-I-dependent efflux, it was anticipated that overexpression of ABCA1 in 
cells and in animal species should enhance the apoAI-dependent cholesterol and 
phospholipid efflux. Indeed, overexpression of ABCA1 in mouse macrophages enhanced 
cholesterol efflux (74) further supporting the key role of ABCA1 in apoA-I-dependent 
cholesterol efflux from cells. Abca1 gene located on chromosome 9 has 50 exons and 49 
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introns (75). Two separate groups of researchers used Bac clones containing Abca1 for 
the generation of transgenic mice (76,77), whereas one group used ABCA1 cDNA for 
making transgenic mouse line (78). 
Two transgenic mouse lines were produced by Cavalier et al. (76), one containing 
255 kb genomic fragment having 36 kb 5′ upstream region from the transcription start 
site and 15 kb 3′UTR region. The other mouse line was made from a 171 kb genomic 
fragment containing the same 15 kb 3′ UTR region, but had only exon 1 sequences in the 
5′ region. They used FVB mouse for making transgenic line. The mouse expressing 255 
kb transgene showed expression in many tissues with macrophage showing enhanced 
cholesterol efflux. The 171 kb transgene mouse line showed expression in liver, but not 
in macrophages, suggesting the presence of a regulatory element in the 5’ upstream 
promoter of the Abca1 responsible for macrophage-specific expression of ABCA1 and 
cholesterol efflux. Most notably, the total- and HDL cholesterol in both ABCA1 
transgenic lines did not change. Singarajaja et al. (77) used genomic DNA with natural 
ABCA1 promoter (10 kb) in C57BL background, and showed that the overexpression of 
ABCA1 increased HDL and cholesterol efflux in macrophages. They also observed 
increased ABCA1 mRNA and HDL in non-transgenic and transgenic mice fed 
atherogenic diet. Vaisman et al. (78) cloned full-length ABCA1 cDNA in pLIV.11 
expression vector with apoE enhancer. Using this transgenic line in C57BL/6 mouse was 
made. Overexpression of ABCA1 increased plasma levels of HDL and increased apoA-I-
mediated cholesterol efflux from macrophages. In an elegant study, they further showed 
that increased plasma levels of HDL occurred by decreased catabolism of HDL. The 
apoA-I production rates did not contribute to increased levels of HDL.  
It should be noted that chow diet used by Singaraja et al. (77) contained cholic 
acid, which was evident from low HDL levels on this diet (HDL 36 mg/dl; non-HDL-C 
28 mg/dL). The other group (78) reported HDL level of 80 mg/dL and non-HDL-chol 7–
10 mg/dl, which makes sense given the published data on HDL levels in several mouse 
strains fed either a chow (no cholic acid) or a high fat (no cholic acid) diet (25,27). Given 
that cholic acid containing diet decreases HDL particles by transcriptional mechanism 
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(79), and increases apoB-containing particles (80), it is not surprising that Singaraja et al. 
(77) noted lower than expected levels of HDL on cholic acid containing chow diet, and 
higher than expected levels of apoB particles. Because bile acids may independently 
influence cholesterol homeostasis via FXR (81) and also via LXR (82), it is possible that 
cholic acid may influence ABCA1 expression. Nevertheless, studies from Singaraja et al. 
(77) demonstrated that atherogenic diet increased ABCA1 mRNA and protein, which 
makes sense given the upregulation of ABCA1 in cholesterol-loaded cells, and increased 
lipid levels in the livers of mice-fed high fat diet (27). These observations were further 
corroborated by another study in wild-type and A-I-CIII-AIV transgenic mice (83). 
Feeding high fat diet for 20 weeks increased hepatic ABCA1 mRNA levels in A-I-CIII-
AIV transgenic mice, which was associated with the atheroprotective effects. The 
reason(s) why two groups noticed HDL elevation in their transgenic mouse lines, while 
the other did not, despite increased cholesterol efflux by isolated macrophages, could be 
due to the differences in the genetic background of mice used for making transgenic line.  
Inbred strains of mice differ in their responsiveness to dietary and hormonal 
interventions (84). Also, it is not necessary that increased ABCA1 expression in 
macrophages would proportionally increase circulating HDL particles (85). An elegant 
study by Haghpassand et al. (86) evaluated the role of macrophage ABCA1 in 
contributing to plasma levels of HDL. They used ABCA1–/– mice created in DBA1Lac/J 
background (70). Bone marrow transplantation was carried out from WT to WT and 
ABCA1–/– mice, and ABCA1–/– to WT and ABCA1–/– mice, resulting into four groups as 
follows: WT → WT, WT → ABCA1–/–, ABCA1–/– → WT, ABCA1–/– → ABCA1–/–. 
Bone marrow transplantation from WT mice resulted increased ABCA1 expression in 
WT and ABCA1–/– macrophages, and bone marrow transplantation from ABCA1–/– mice 
resulted lack of ABCA1 expression in WT and ABCA1–/– recipient macrophages. Despite 
increased levels of macrophage ABCA1 expression there was no change in the plasma 
levels of HDL, suggesting that macrophage ABCA1 contributes very little to maintaining 
plasma HDL levels. Therefore, hepatic ABCA1 expression gives rise to the bulk HDL 
particles. These results combined with other studies suggest that macrophage cholesterol 
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efflux can be a determinant in the prevention of atherosclerosis, but may not contribute to 
the bulk HDL particles. 
6.2.4.  ABCG Transporters and Reverse Cholesterol Transport 
In addition to ABCA1, which effluxes cholesterol to the nascent, discoidal HDL 
particles, there is another player in the pathway of HDL maturation that effluxes 
cholesterol to the doiscoidal HDL particles generated by the action of ABCA1. This 
transporter is known as ABCG1 (24,87,88). ABCG1, one of the half-type ATP binding 
cassette proteins, mediates the efflux of cholesterol to HDL and functions in the reverse 
cholesterol transport from peripheral cells to the liver. ABCG1 also mediate phospholipid 
efflux to human serum and HDL. ABCG1-mediated free cholecterol efflux correlated 
significantly with a number of HDL subfractions and components in serum collected 
from normolipidemic individuals (89). It did not enhance influx of cholesterol or 
cholesteryl oleyl ether (COE) when cells were incubated with radiolabeled HDL and 
expression of ABCG1 did not increase the association of HDL with cells.  
Wang et al (90,91) showed that ABCG1 promotes efflux of cholesterol to a 
variety of acceptors, including HDL and phospholipid vesicles without increasing the 
binding of lipoproteins to cells. ABCG1 also promoted efflux of a broader spectrum of 
sterols including oxysterols, whereas ABCG1 and ABCG4 together promote efflux of 
sterol intermediates from the cholesterol synthesis pathway such as desmosterol (92). A 
number of ABCs involved in lipid transport are regulated through activation by LXR, and 
these include ABCA1 (93), ABCG1 (90), and ABCG4 (90). However, studies with 
ABCG4 -/- mice suggested that ABCG4 is not expressed in macrophages and does not 
contribute to HDL-mediated cholesterol efflux (94). 
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Fig. 4.  ABCA1-and ABCG1-mediated cholesterol efflux requires energy in the two-step HDL 
maturation. Lipid-poor discoidal HDL particle in the circulation becomes lipidated by 
ABCA1using ATP followed by ATP-dependent maturation of HDL by ABCG1.  
Interestingly, overexpression of ABCG1 increases efflux of not only cellular 
sterols but also, to some extent, cellular phospholipids. (90,95,96). Overexpression of 
ABCG1 results in increased cell membrane cholesterol pools available for efflux and 
increases the rate constant for efflux; efflux appears to be diffusional and unidirectional 
and is more efficient for smaller HDL particles (89). Different models have been 
proposed to explain how ABCG1 promotes cholesterol efflux to HDL. One suggests that 
ABCG1 helps sterol molecules to overcome the energy barrier for entry into the 
hydrophilic water layer, perhaps by using ATP to promote protrusion of the cholesterol 
molecule into water, followed by a transient collision with an acceptor (97). A second 
model points to a function of ABCG1 as a phospholipid floppase (95), promoting 
changes in the organization of plasma membrane phospholipids and subsequent attraction 
of sterols to the outer leaflet for diffusional efflux. Another possibility is that ABCG1 
promotes flopping of cholesterol in liquid ordered regions of plasma membrane such that 
spontaneous flipping of sterol back to the inner membrane is not possible.  
The incubation of apoA-I with J774 mouse macrophages expressing ABCA1 (66) 
leads to the efflux of cholesterol and phospholipid and the subsequent formation of 
nascent high density lipoprotein (HDL) particles (98). ABCG1 transcription is highly up-
regulated in cholesterol loaded macrophages (99), and ABCG1 facilitates the efflux of 
cholesterol from cells to HDL, rather than to free apoA-I (90,100,101). The peroxisomal 
proliferator activated receptor-γ (PPAR-γ) activators also increase ABCG1 transcription 
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in macrophages and stimulate cholesterol efflux to HDL independent of their induction of 
LXR (102). Like ABCG1, ABCG4 also facilitates the efflux of cholesterol from cells to 
HDL (87,90), although there is evidence that ABCG1 and ABCG4 can form a 
heterodimer (103). ABCA1 and ABCG1 have been shown to synergize to mediate the 
efflux of cholesterol to apoA-I (88). These findings suggest a significant role for ABCG1 
and possibly ABCG4 in the release of cholesterol from cells into the reverse cholesterol 
transport pathway. The importance of macrophage ABCA1 expression in atherosclerosis 
has been demonstrated in mice, where the bone marrow transplantation of ABCA1 null 
macrophages was shown to lead increased atherosclerosis in hyperlipidemic animals 
(104). Conversely, the over-expression of macrophage ABCA1 in mice reduces 
atherosclerotic lesion development in low-density lipoprotein receptor deficient mice 
(105). The targeted disruption of ABCG1 in mice on a high fat and high cholesterol diet 
causes the massive accumulation of both neutral lipids and phospholipids in hepatocytes 
and macrophages of multiple tissues (24). Conversely, tissues in ABCG1 transgenic mice 
are protected from dietary fat-induced lipid accumulation (24). The efflux of cholesterol 
to these particles is dependent both on apoA-I concentration used to efflux lipid from 
ABCA1 and on the time the particles are incubated with ABCG1 and ABCG4 expressing 
cells. The cholesterol released from the ABCG1 and ABCG4 expressing cells by HDL 
comes mainly from a cell-surface cholesterol domain that is formed upon expression of 
the transporters (87). 
6.2.5. ABCA1 Regulation 
Considerable work has been done on the regulation of ABCA1. Most of the 
studies focused on the transcriptional regulation, although some attempts have been made 
to investigate posttranscriptional regulation of the ABCA1. A number of researchers have 
shown that cholesterol efflux to apoA-I in macrophages is highly inducible by cyclic 
AMP analogs, which was attributed to the transcriptional upregulation of ABCA1 
(106,107). Oram et al. (66) showed that incubation of macrophages with 8-Br-cAMP 
stimulated ABCA1 protein and mRNA, with highest level achieved after 24 h incubation. 
Withdrawal of 8-Br-cAMP resulted in bringing the ABCA1 protein and mRNA to the 
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basal level within 2–6 h, suggesting that ABCA1 protein is highly unstable and gets 
degraded in the absence of 8-Br-cAMP. First study showing cAMP-mediated induction 
of cholesterol efflux through ABCA1 phosphorylation was demonstrated in fibroblasts 
(108). These authors further showed that apoA-I activated cellular cAMP signaling 
through ABCA1(109). Further studies with ABCA1 promoter in the presence and 
absence of cAMP response elements confirmed (110) the results of Oram et al. (66) and 
Haider et al (108). These authors also demonstrated (110) the role of PKA in cAMP-
mediated upregulation of ABCA1 gene expression, since protein kinase A has been 
implicated in the cAMP-mediated regulation of target genes via phosphorylating a 
transcription factor, CRE-BP1 (cAMP response element binding protein 1), which binds 
to the cAMP response element, and drives the transcription of target genes. Experiments 
with non-macrophage cells with cloned ABCA1 gene in front of heterologous promoter 
with CRE-BP1 element will be needed to prove the hypothesis that cAMP-mediated 
response occurs through PKA-mediated pathway primarily at the transcription level. 
The cloning of ABCA1 gene and its promoter enabled the analysis of ABCA1 
structure and function. In addition to functional regulatory domains in the exon 1, an 
LXR element was recently reported in the intron 1 sequences (77). The nalternative 
splicing of ABCA1 gene gives rise to two splice variants. The ABCA1 promoter, in 
addition to TATA box and CAAT box, also contains other potential regulatory sites. An 
imperfect direct repeat of the nuclear receptor half sitenTGACCT spaced by 4 
nucleotides (DR4) bind to the LXR/ RXR heterodimers, and mutation in the DR4 
abolished the oxysterol-responsive ABCA1 activation, suggesting that DR4 is important 
in LXR/RXR-mediated upregulation of ABCA1, as well as for oxysterol-induced 
activation of ABCA1 (85,111). Two separate regions of ABCA1 promoter appears to be 
important in the transcriptional activations of ABCA1, the E-Box motif located –147 bp 
upstream that binds to transcriptional factors USF1 and 2. It also binds to the 
transcriptional repressor Fra2. LXR-α is stimulated by its ligand, oxysterols, and binds as 
a heterodimer (LXR/RXR) to the DR4 and activates the transcription of ABCA1. In vivo 
studies in mice have confirmed that LXR is an important activator of ABCA1 (85).  
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cAMP has been shown by several researchers as an activator of ABCA1 by 
transcriptional mechanism, since increased ABCA1 mRNA by cAMP does not involve 
ABCA1 mRNA stability (66). This implies that a cAMP response element should be 
present in the ABCA1 promoter. Indeed, a cAMP response element in the ABCA1 
promoter has been identified (110), which appears to drive effect of cAMP on the 
transcriptional activation of ABCA1, although detailed study showing involvement of 
CREBP on transcription of ABCA1 gene was not shown. In order for cAMP to regulate 
transcription of the target gene in a given cell line, the expression of CRE-BP (cAMP 
response element binding protein) in that cell line appears to be a prerequisite. Future 
researches will focus on how regulation of ABCA1 gene by cAMP is coordinated at the 
transcription, translation and post-translation level. The transcriptional repressor ZNF202 
(112) was mapped to chromosome 11q23 and was found to be associated with 
hypoalphalipoproteinemia. Since mutations in ABCA1 were also shown to be associated 
with hypoalphaproteinemia, it was anticipated that a link between ABCA1 and ZNF202 
exists. Using transfection and mutational studies, it was demonstrated that ZNF202 binds 
to the GnT motif of ABCA1 promoter and mediates the transcriptional repression (112). 
Therefore, ZNF202 is an interesting candidate to modulate cholesterol efflux via 
ABCA1-mediated pathway. 
6.2.6. ABCA1 and Atherosclerosis 
The removal of excess cholesterol from macrophage foam cells by HDL and its 
principal apolipoprotein, apoA-I, is thought to be one of the key mechanisms underlying 
the atheroprotective properties of HDL. Insights gained from ABCA1 heterozygotes are 
indicative of ABCA1’s cardioprotective effects (113). An analysis of 77 individuals from 
11 families suggested that ABCA1 heterozygotes had about 40–45% decrease in HDL 
levels and 40% increase in triglyceride level compared to unaffected controls. The 
decreased levels of HDL were also found to be associated with the decreased cholesterol 
efflux by fibroblasts, suggesting a direct association between circulating HDL levels and 
cholesterol efflux. These researchers went on further to explore a correlation between 
HDL cholesterol/cholesterol efflux and intima-media complex thickness (IMT) of 
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peripheral arteries in these heterozygotes. Interestingly, the increased IMT was correlated 
with decreased cholesterol efflux and about 25 years earlier onset of progression of 
atherosclerosis than the unaffected controls. These data clearly demonstrate that the 
removal of cholesterol from artery wall (both ABCA1- dependent and ABCA1-
independent) is associated with atheroprotection, and defect in cholesterol efflux 
predisposes an individual to premature atherosclerosis. Thus, small increases in 
cholesterol efflux may have significant impact on the extent of atherosclerosis as 
measured by the intimal thickness (61,113). Therefore, given the data that more than 60% 
of patients with cardiovascular disease have normal LDL levels, the cholesterol efflux is 
a good target to reduce the risk of atherosclerosis, and given the important role of 
ABCA1 in apoprotein-mediated cholesterol efflux, it is possible to modulate cholesterol 
efflux by modulating ABCA1 expression.  
The data from two different groups (77,78) are in agreement with regard to the 
elevated levels of HDL, cholesterol efflux and recently with regard to the inhibition of 
atherogenesis in ABCA1 transgenic mice (22), and in A1-CIII-AIV transgenic mice (83). 
Overexpression of ABCA1 in diet-induced atherosclerosis susceptible mice C57BL/6 
resulted in decreased atherogenic particle by half and increased HDL levels 2.8-fold. 
ApoE and apoA1 levels also increased in these mice by more than 2-fold (22). These 
changes were associated with significantly lower (65%) aortic atherosclerosis, 
demonstrating that ABCA1 has antiatherogenic properties, possibly via removing 
cholesterol from the arterial wall, since HDL levels increased more than 2-fold and LDL 
levels decreased 2-fold. In addition, increased apoE levels in ABCA1- transgenic mice 
may have further contributed to the inhibition of progression of atherosclerosis via 
removal of the atherogenic particles from the circulation, and cholesterol from lipid-laden 
macrophages. However, when these mice were crossed with apoE–/– mice, the protective 
effect of ABCA1 was lost, and as a result, ABCA1 transgenic mice having apoE–/– 
background showed more atherosclerosis (22). Given the enhanced cholesterol efflux in 
ABCA1 over-expressing mice, one would expect the double mutant mice ABCA1-Tg x 
apoE–/– to show inhibition of atherosclerosis. To further have insights into the role of 
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ABCA1 in the inhibition of atherosclerotic lesion formation, bone marrow transplantation 
technique was used. They used either WT or ABCA1–/– mouse line for bone marrow 
transplantation into irradiated LDLr–/– mice similar to a recent study (86). As determined 
by PCR, they showed more than 90% of bone marrow cells were from donor origin. No 
changes in the lipoprotein profiles were noticed either on chow or on high fat diets. These 
results clearly established that ABCA1 is protective against development of 
atherosclerotic lesion formation, and the absence of ABCA1 promotes lesion formation in 
LDLr deficient mice fed high cholesterol high fat diet for 12 weeks. These results are 
consistent with another study showing no changes in the circulating levels of HDL 
following bone marrow transplantation from WT to ABCA1–/– mice (86). Clee et al. 
(113) showed that ABCA1 heterozygotes and homozygotes had more prevalence and 
severity of atherosclerosis than the unaffected controls. They also showed that 
heterozygotes had an earlier onset of coronary artery disease. These studies together with 
ABCA1 transgenic mice suggest that ABCA1 protects individuals from developing 
premature atherosclerosis. Based on these results the role of ABCA1 in atheroprotection 
is schematically depicted in Fig. 5. 
                                         
Fig. 5.  Schematic representation of atheroprotective effects of ABCA1. Lipid-laden macrophages in the 
arterial walls set the stage for the initiation of atherosclerosis via a variety of mechanisms. The 
removal of lipids form the macrophages are therefore a prerequisite in the process of inhibition of 
atherosclerosis. ABCA1-elevating agents and stimuli accelerate the removal of cholesterol and 
phospholipids from the lipid-laden macrophages, and reduce the risk of predisposition to 
atherosclerosis. 
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6.3 Nuclear Hormone Receptors Mediated Cholesterol Efflux 
Incubation of human and murine macrophages with lipoproteins, oxysterols, and 
oxidized LDL induced ABCA1 mRNA concomitant with increased levels of LXRα 
expression (93,111,114,115). Both RXR as well as LXR agonists induce ABCA1 
expression as measured by ABCA1 mRNA levels. Repa et al. (85) identified the 
heterodimeric partner of LXRα responsible for the induction of ABCA1 mRNA by LXRα 
agonists, and showed that both RXR and LXR agonists induce ABCA1 mRNA in 
duodenum, jejunum and ileum, but not in the liver. Treatments of macrophages with the 
RXR and LXR-selective agonists induced ABCA1 expression, suggesting that ABCA1 is 
the direct target gene of RXR/LXR activation. LXR agonist, T0901317, did show 
induction of ABCA1 in cultured cells (116) and in animal models (117,118). This was 
also corroborated by studies in LXRα and LXRβ KO mice, which failed to show effects 
on ABCA1 following treatments with RXR and LXR agonists. Thus, RXR and LXR 
agonists, in addition to influencing cholesterol efflux, also inhibit cholesterol absorption 
by inducing ABCA1 in the gut. 9-cis retinoic acid alone or in combination with 
oxysterols induces ABCA1 mRNA (93). Retinoic acid receptor mediated induction of 
ABCA1 has been reported in macrophages (119). RXR agonists ((85,93), LXR-α 
agonists (85), and PPAR-α and PPAR-γ agonists (120,121) induce the transcription of 
ABCA1. Addition of PPAR and LXR-α agonists showed additive effects on ABCA1 
upregulation, suggesting that these agonists influence ABCA1 transcription via 
independent mechanism. PPARα and PPARγ receptors are nuclear receptors that 
heterodimerize with RXR to modulate the expression of target genes involved in lipid 
and glucose metabolism. The ligands for PPARα and PPARγ induce ABCA1 mRNA in 
primary human macrophages (120). Since LXRα was also induced by PPARα and γ 
agonists, and since ABCA1 promoter harbors LXR element, it suggests that PPARα and γ 
agonists induce ABCA1 gene expression via LXR-mediated pathway (120). Although 
studies with macrophages isolated from LXR KO mice will be necessary to confirm that 
indeed PPARα and γ agonists induce ABCA1 gene expression via LXR-mediated 
pathway, the absence of PPAR element in ABCA1 promoter and the presence of PPAR 
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element in the LXR promoter (122) do suggest the likelihood of LXRmediated 
upregulation of ABCA1 by PPARα and γ agonists. Indeed, another PPAR receptor, 
PPARδ, expressed in many tissues, has been implicated in the regulation of ABCA1 gene 
expression (123). A recent study (124) with PPARδ-specific agonist, demonstrated 
upregulation of ABCA1 mRNA, which was associated with increased plasma levels of 
HDL.  
               
Fig. 6. Nuclear hormone receptor upregulates ABCA1 and G1, which effluxes cholesterol from lipid-
laden macrophages in the arterial walls and inhibits atherosclerosis. Inflammation and oxidative 
stress impairs cholesterol efflux.  
 
At least in two studies ABCA1 was found to be down-regulated. In one study, 
treatments of macrophages with IFN-γ reduced ABCA1 mRNA and cholesterol efflux to 
apoA-I acceptor (125), suggesting that IFN-γ may promote foam cell formation and 
accelerate the progression of atherosclerosis. A recent study demonstrated that 
geranylgeranyl pyrophosphate, a major metabolite in the mevalonate pathway, is a potent 
suppressor of ABCA1 by acting as an antagonist of LXR, and also by Rho GTP binding 
proteins (126). Several studies have indeed shown that LXR agonists inhibit progression 
of atherosclerosis in LDLr deficient (127-129) and apoE-deficinet (130) mice, and 
promote regression of preformed lesion in the aorta of apoE3*Leiden (128) and 
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hyperlipidemic hamsters (131). Similarly PPAR-α and PPAR- γ agonists also inhibit 
atherosclerosis (102,132,133) and regresses preformed lesion (131). The antiatherogenic 
effect of LXR agonists appears to occur via induction of the macrophage ABCA1 (116) 
(Figure 6). 
6.4. Diabetes, HDL, Oxidative Stress, and ABCA1  
Type 2 diabetes mellitus and the cluster of pathologies characteristics of 
metabolic syndrome including insulin resistance, obesity, and high plasma triglycerides 
are often associated with low HDL and shown to be dysfunctional as a result of the 
formation of advanced glycation endproducts (134,135). In contrast, individuals doing 
intensive exercise have high HDL and also show improved glucose tolerance (136), 
suggesting a link between low HDL and energy metabolism. Given the higher prevalence 
of cardiovascular morbidity and mortality in diabetics, this is an important area to pay 
attention to. Recent cell-based studies suggest that HDL may modulate plasma glucose 
through both insulin-dependent (137,138) and –independent and AMPK-mediated 
mechanisms (139). The ATP-binding cassette transporter A1 (ABCA1) has been shown 
to modulate insulin secretion (138), and HDL can reverse the deleterious effects of 
oxidized low-density lipoprotein (LDL) on insulin secretion by pancreatic beta cells 
(137). In addition, HDL may also increase glucose disposal through direct effects in 
skeletal muscle, the major site of glucose disposal in the body. It was reported that HDL 
and its major apolipoprotein, apolipoprotein A-I (apoA-I), activate the key metabolic 
regulatory enzyme AMP-activated protein kinase (AMPK) in endothelial cells and are 
critical for the nitric oxide–mediated vasodilatory effects of HDL (140). Infusion studies 
with recombinant and reconstituted HDL (rHDL) demonstrated modest effects on 
coronary plaque morphology and volume (47,141) and also showed improved endothelial 
function in type 2 diabetes mellitus (142).  
The systemic metabolic disturbances of diabetes, including hyperglycemia and 
hyperlipidemia, likely play a central role in the pathogenesis of diabetes-associated 
atherosclerosis through the generation of oxidative stress and inflammation. 
Hyperglycemia causes increased flux through the polyol pathway, formation of advanced 
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glycation end products, activation of protein kinase C isoforms, and increased 
hexosamine pathway flux, all of which may contribute to increased oxidative stress (143-
145). Excessive free fatty acids delivered to nonadipose tissues can lead to reactive 
oxygen species (ROS) formation through cycles of oxidative phosphorylation, activation 
of NADPH oxidase, and alterations in mitochondrial structure that precipitate ROS 
production (146-148). In addition to evidence for activation of these pathways in cultured 
endothelial cells, human studies support the notion of increased systemic oxidative stress 
in diabetic subjects in whom increased circulating levels of adhesion molecules and 
oxidized lipids correlate with increases in HbA1c and hypertriglyceridemia (149). The 
effects of oxidative stress in diabetes on both the vascular wall and lipoproteins in the 
circulation may promote atherogenesis. Jaleel et al. (150) provided intriguing evidence 
that poor glycemic control in type-1 diabetes is associated with accelerated oxidative 
damage to apoA-I, the main protein component of HDL. These investigators adapted a 
pulse-chase approach, classically used in cell culture experiments, to label newly 
synthesized proteins with 13C-phenylalanine in human subjects. They then analyzed 
various plasma apoA-I isoforms by two-dimensional gel separation and mass 
spectrometry. This approach enabled quantification of isotopic enrichment in newly 
synthesized forms of the protein containing the propeptide and in more mature cleaved 
forms, which together form a charge train of five spots in two-dimensional gel analyses. 
The older forms of apoA-I accumulated significantly more, suggesting damage as a result 
of deamidation, oxidation, and carbonylation of amino acids that likely contributed to 
their altered migration in isoelectric focusing.  
Given that apoA-I is a major component of HDLs, which protect against 
atherosclerosis by facilitating the removal of cholesterol from macrophages in the arterial 
wall and promoting reverse cholesterol transport, obvious extensions of this work will be 
to determine if the changes observed by Jaleel et al. (150) in apoA-I forms are due 
directly to oxidative stress. Indeed, recent studies demonstrated the presenc of significant 
amounts of oxidation products of apoA-I in human atherosclerotic plaques (151,152). 
Additionally, studies just published showed that myeloperoxidase enzyme that causes 
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oxidation of apoA-I, predict accelerated progression of atherosclerosis in diabetics (153). 
Thus, these studies provide mechanistic insight into the etiology of the oxidative 
modification of apoA-I and also how the functionally of HDL is linked to increased 
cardiovascular risk in diabetes. 
Diabetic individuals often have higher non-esterified fatty acids that may impact 
ABCA1-mediated cholesterol efflux. Indeed, Wang and Oram (154) demonstrated that 
unsaturated fatty acids inhibit ABCA1-mediated cholesterol efflux. This finding is very 
important given the elevated levels of fatty acids in diabetics (155), and enhanced apoB 
secretion by fatty acids as a result of impaired presecretory degradation of apoB 
(26,60,156). It therefore appears that ABCA1 could be important not only in the 
inhibition of progression of atherosclerosis, but also in metabolic diseases. Wang and 
Oram (154) studied the effects of fatty acids, ranging in carbon chain length from 8 to 20, 
on cholesterol and phospholipid efflux in murine J774 and RAW 264.7 cells. The 
saturated fatty acids, palmitate and stearate, neither inhibited ABCA1- mediated 
cholesterol and phospholipid efflux nor they influenced ABCA1 protein. However, 
unsaturated fatty acids, oleate and linoleate, reduced cholesterol efflux as well as ABCA1 
protein in a dose-dependent manner. Interestingly, oleate and stearate did not alter 
ABCA1 mRNA. As determined from ABCA1 turnover studies, it was concluded that 
unsaturated fatty acids enhanced the degradation of ABCA1 protein. These authors 
looked into the mechanism of fatty acid-mediated degradation of ABCA1 and carried 
elegant studies to demonstrate that unsaturated fatty acids phosphorylate and destabilize 
ABCA1 through a phospholipase D2 pathway (157). Further studies revealed that protein 
kinase C delta pathway is also involved in this process (158). Thus, it appears that the 
triggering of the the ABCA1 degradation by fatty acids possibly occurs via a mechanism 
distinct from the one observed with the cAMP withdrawal (66). 
6.4.1. HDL, ApoA-I and AMPK  
The role of apoA-I, the main protein component of HDL lipoproteins, on energy 
and glucose metabolism was first investigated by Han et al. (139) in C2C12 myocytes. 
These investigators reported AMPK phosphorylation at Thr-172 following treatments 
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with apoA-I, and this effect was found to be specific to apoA-I protein since treatment 
with apoB did not result into AMPK phosphprylation. ApoA-I also increased glucose 
uptake by C2C12 cells similar to AMPK activatos (159). These effects were similar to 
the activation of AMPK by adiponectin leading to increased glucose uptake (160). These 
authors extended their cell-based studies into apoA-I -/- mice to support their hypothesis 
that apoA-I is involved in glucose and energy metabolism. Indeed, apoA-I -/- mice had 
higher circulating glucose and impaired glucose tolerarce. Based on these findings Drew 
et al (161) extended these studies in human primary skeletal muscle cells isolated from 
type 2 diabetic patients infused with either a placebo or reconstituted HDL. They reported 
reductions in the fasting glucose in the rHDL treated group as compared to the placebo 
group. In cultured primary human skeletal muscle cells, apoA-I, the main protein 
component of HDL increased glucose uptake by 50%, which was associated with the 
activation os AMPK as measured by the AMPK phosphorylation at Thr-172. To further 
gain insights into the mechanism of apoA-I/HDL-mediated AMPK activation, these 
authors looked into two primary pathways of AMPK activation, i.e. LKB1 and CaMKK, 
the two upstream kinases known to phosphorylate AMPK (162,163). They found that 
HDL-mediated induction of AMPK phosphoryltion occurs via CaMKK-mediated 
pathway, since the CaMKK inhibitor STO609 abolished HDL-mediated phosphorylation 
of AMPK. Interestingly, the HDL-mediated induction of skeletal muscle glucose uptake 
occurred in ABCA1-dependent manner, since ABCA1 blocking antibody inhibited apoA-
I and HDL-mediated uptake of glucose (161). 
6.5  HDL, Inflammation, and Reverse Cholesterol Transport 
Atherosclerosis has been characterized as a chronic inflammatory response to 
cholesterol deposition in arteries, but the mechanisms linking cholesterol accumulation in 
macrophage foam cells to inflammation are not completely understood. One of the 
mechanisms to protect cells from free cholesterol and oxysterol-induced toxicity during 
progression of atherosclerosis is the macrophage cholesterol efflux. During the 
cholesterol efflux process, the ATP-binding cassette transporters ABCA1 and ABCG1 
are important players responsible for the major part of macrophage cholesterol efflux to 
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HDL in macrophage foam cells. Recent studies have shown that the sterol efflux 
activities of ABCA1 and ABCG1 modulate macrophage expression of inflammatory 
cytokines and chemokines as well as lymphocyte proliferative responses. Accumulating 
evidence suggests that by promoting cholesterol and oxysterol efflux, HDL regulates all 
these cellular responses in macrophage foam cells. Indeed, several studies demonstrated 
that native and reconstituted HDL, apoA-I and apoA-I mimetic peptides, all show anti-
inflammatory activity (164-169). ABCA1 and ABCG1 deficiency in macrophages causes 
increased signaling via various Toll-like receptors including TLR4. These studies have 
also shown that the primary function of HDL and ABC transporters in cholesterol efflux 
and reverse cholesterol transport are also mechanistically linked to antiinflammatory and 
immunosuppressive functions of HDL. The potent antiinflammatory properties of HDL 
and apoA-I occurs throrugh a number of mechanisms, including the ability of HDL to 
bind and sequester lipopolysaccharide (170,171), resulting in the suppression of Toll-like 
receptor 4 (TLR4) signaling (172). HDL-mediated cholesterol efflux inhibits cellular 
inflammatory signaling leading to inhibition of MCP-1 and CD11b expression and 
monocyte transmigration.  
Mice lacking ABCA1 and ABCG1 accumulate inflammatory macrophage foam 
cells not only in the myocardium but also in various tissues such as in the lung, liver, 
spleen, or thymus. Several studies have shown that the increased lipid raft formation in 
macrophages with genetic deficiencies of ABCA1 (173-175) or ABCG1 (176) could 
account for the enhanced inflammatory responses, especially after treatment with LPS or 
other TLR ligands leading to enhanced signaling via Myd88-NFkB. Replenishment or 
removal of cholesterol using cyclodextrin modulates the inflammatory response of 
macrophages deficient in ABCA1 or ABCG1, indicating that the increased inflammatory 
response is likely attributable to cholesterol accumulation in membranes (Figure). Yuvan-
Charvet et al (175) showed that by modulating membrane cholesterol, deficiency of 
ABCA1 or ABCG1 increased TLR4 cell surface expression. Recently, Bensinger et al 
(177) reported that Liver X Receptor (LXR) signaling is involved in T-cell lymphocyte 
proliferation in an ABCG1-dependent fashion. ApoA-I KO mice also develop T-cell 
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proliferation and activation and features of autoimmunity when backcrossed into an LDL 
receptor– deficient background (178). These studies strongly suggest that HDL-mediated 
cholesterol efflux via LXR-regulated ABC transporters plays a key role in dampening 
lymphocyte proliferation and activation.  
Poor glycemic control in type-1 diabetes is associated with accelerated oxidative 
damage to apolipoprotein (apo) A-I, the main protein component of HDL (150) and 
advanced glycated albumin diminishes anti-inflammatory properties of HDL (179,180). 
Reconstituted HDL (rHDL) shows anti-inflammatory activity in humans (164,168,181). 
ABCA1-mediated cholesterol efflux capability of HDL is compromised in type 2 
diabetes patients (182), possibly as a result of oxidative damage of apoA-I and increased 
inflammation (183,184). Since antioxidative and antiinflammatory properties of HDL are 
impaired in diabetics (184), oxidative stress and inflammation may contribute to HDL 
dysfunction (185). HDL undergoes modification and multiple structural changes in an 
inflammatory condition and transforms normal functional HDL into “acute phase HDL”, 
enriched in free fatty acids, triglycerides, serum amyloid A (SAA), and decreased 
antiinflammatory enzymes, including paraoxanase 1 (186,187). In addition, inflammation 
induces secretion of myeloperoxidase (MPO), which has been shown to modify 
apolipoprotein A-I and impair its ability to accept cholesterol (151,188-191). MPO-
mediated oxidation of apoA-I makes it proinflammatory (192). Tryptophan substitution 
in apoA-I renders it resistance to MPO oxidation (193). All these studies suggest that 
increase in inflammation leads to HDL dysfunction.   
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7. MATERIALS & METHODS 
7.1 Materials 
7.1.1 Clones, Vectors and Probes 
ABCA1 expressing stable human embryonic kidney 293T cell line was generated 
by Flip-In system (Invitrogen). Full-length human ABCA1 cDNA was isolated from 
cultured human skin fibroblast cells and cloned into pcDNA5/FRT vector (Invitrogen).  
Following probes were used for the quantitation of mRNA in mouse tissues. 
 
To generate ABCA1 monoclonal stable cell line, 293 cells were co-transfected with 
pcDNA5/FRT-ABCA1 and pOG44 (Invitrogen) using Fugene-6 (Roche) in the growth 
medium without zeocin according to manufacturer’s recommendations. After 24 h 
Species Gene 
Forward Primer 
Sequence 
Reverse Primer 
Sequence Probe Sequence 
Amplicon 
Length 
MOUSE Cyclophilin 
CGATGACGAGCC
CTTGG 
TCTGCTGTCTTTGGA
ACTTTG 
CGCGTCTCCTTTG
AGCTGTTTGCA 64 
MOUSE ABCA1 
GCTCTCAGGTGG
GATGCA 
GCTCGTCCAGAATG
ACAA 
CTTGGCCTTCGTG
GGTGGATCC 78 
MOUSE ABCG1 
ATCTGAGGGATC
TGGGTCT 
CCTGATGCCACTTCC
AT 
CTGCCCTACCTAC
CACAACCCAGCA 67 
MOUSE ABCG5 
TACACCGGCATG
CTCAATG 
GGCCATCCTGACTCT
CCTG 
TCTGTTTCCCATG
CTGAGAGCCGT 76 
MOUSE ABCG8 
GTCGTCAGATTTC
CAATGAC 
AGGGACATCAGGCA
GGCTT 
GGGACCTGCCCA
CGCTG 75 
MOUSE SREBP1c 
CGTCTGCACGCCC
TAGG 
CTGGAGCATGTCTTC
AAATGTG 
AATCCATGGCTCC
GTGGTCCG 70 
MOUSE FAS 
CGGAAACTTCAG
GAAATGTCC 
TCAGAGACGTGTCA
CTCCTGG 
CCAAGACTGACT
CGGCTACTGACA
CGAC 82 
MOUSE SCD-1 
TGTACGGGATCA
TACTGGTTCC CCCGGCTGTGATGCC 
TGCCTCTTCGGGA
TTTTCTACTACAT
GAC 95 
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following transfection, cells were maintained in DMEM with 10%FBS and 50 µg/ml 
hygromycin. Individual colonies were examined for the expression of ABCA1 by 
Western blotting. 
7.1.2 Growth media 
The complete D-MEM medium containing 10% FBS supplemented with 0.1 mM 
MEM non-Eessential amino acids, 1 mM sodium pyruvate and 2 mM L-glutamine was 
used to culture 293 cells.  
7.1.3 Animal Models 
All studies were carried out in C57Bl male mice until and unless indicated. Other 
animal models used in this study were LDLr-/-, ob/ob, apoA-I transgenic, LDLr-/-/ob/ob 
double knockout. 
7.2 Methods 
7.2.1 Cell culturing and Transient Transfection 
WT human embryonic kidney 293 cells maintained in D-MEM with 10% FBS, 
50U/ml penicillin streptomycin was used for transfection of ABCA1 construct. The 
details of the stable transfection have been described (194). HepG2 cells were transfected 
with 12 mg plasmid containing apoA-I promoter, and cotransfected with 5 mg of a-gal 
plasmid to account for the transfection efficiency. Transfection was performed using a 
commercial kit obtained from Promega, and by following the protocol provided by the 
manufacturer. Chloremphenicol acetyl transferase activity in the hepatocytes was 
normalized with Gal activity as described previously (194).  
7.2.2 Cholesterol Efflux Assay 
For cholesterol efflux assay, cells (4x104 /ml) were seeded in 24 well plates. Next 
day labeling media (culture medium plus 1% FBS with 2 mCi/ml [3H] cholesterol) was 
added to the cells at 0.5 ml/well. After 24 h of incubation, the cells were switched to 
0.2% BSA (defated, Sigma) in serum-free medium for 3 h to equilibrate radiolabeled-free 
cholesterol. Medium was removed and cells were incubated in serum-free culture 
medium with or without ApoAI (final concentration 10 mg/ml) and with or without 8-Br-
cAMP (0.3 mM) for 24 hours. One hundred microliter of the medium was removed and 
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counted on a liquid scintillation counter. For cholesterol efflux quantitation, cells were 
first solubilized by adding 500 µl of 0.1N NaOH to each culture plate well, and then 100 
µl of supernatant was removed and counted on a liquid scintillation counter. The amount 
of cholesterol efflux was calculated as follows: Cholesterol efflux = Total radioactivity in 
the medium/(Total radioactivity in the medium + Total radioactivity in the cells) 
7.2.3 ABCA1 Protein Assay  
After each experiment, the cells were collected by spinning, and lysed in lysis 
buffer (20 mM Hepes, 5 mM KCl, 5mM MgCl2, 0.5% (v/v) Triton X-100 and complete 
protease inhibitor). Cell debris was removed by centrifugation at 8000 rpm for 10 min at 
4°C. Protein concentration in the supernatant was determined by BioRad protein assay 
kit. 25 microgram of protein was separated on a 8-16% Tris- Glycine gel (Pre Cast 
Invitrogen gels) and electrophoretically transferred to nitrocellulose membrane 
(Invitrogen). Membranes were probed with either ABCA1 antibody or a polyclonal anti-
beta actin antibody (Santa Cruz Biotechnology) as a control for equal loading. 
Immunoreactivity was detected by Super signal (Pierce).   
7.2.4 ABCA1 mRNA Quantitation 
Gene- specific primers and probe were designed using the Primer Express 
software (Perkin Elmer Life Sciences). The real time RT-PCR reaction was performed 
essentially following the manufacture’s protocol with RT-PCR mix and 200 nM FAM-
probe and 600 nM of both forward and reverse primers, and was analyzed in ABI prism 
7900HT sequence detection system (Applied Biosystems). Relative amounts of ABCA1 
mRNA levels were plotted as fold-change compared to no treatment. For normalization, 
18S ribosomal RNA was used. Taqman RT-PCR was performed in triplicate and 
experiment was independently repeated three times 
7.2.5. Experiments with 8-Br-cAMP and Protein Kinase Inhibitors  
Effects of addition of 8-Br-cAMP and protein kinase inhibitors were studied in 
nontransfected as well as in the stably transfected 293 cells. Cells were treated with 8-Br-
cAMP (Sigma) (0.3 mM final concentration) for 24 hr as described (22). To perform 
experiment with PK inhibitors, cells were first treated for 3 h with PK inhibitors, H7, H8 
 
 
44 
or H9 (Sigma) at the final concentration of 15 µM followed by the addition cAMP 
together with PK inhibitors for 24 hrs. Parallel experiments were performed without PK 
inhibitor and without 8-Br-cAMP. After each treatment, cholesterol efflux, ABCA1 
protein, and ABCA1 mRNA were measured. 
7.2.6. Fecal Cholesterol Measurements in Non-radioisotopic Studies 
Fecal cholesterol were measured using a shortened method of Homan et al. (195). 
In brief, 100mg of each fecal sample was homogenized for 20 seconds in 0.50 mL (150 
mM NaCl/5mM MOPS/1 mM EDTA/0.01% PMSF) followed by the addition of 0.5 mL 
of (150 mM NaCl 5mM MOPS/1 mM EDTA) and 200 µL of internal standard (2.0 
mg/mL eicosanol in 2:1 MeCl2: MeOH).  Samples were extracted with 2.0 mL of (2:1 
MeCl2: MeOH) with vortex and subsequent centrifugation at 1500 rpm to separate and 
remove the lower organic layer. The extraction procedure was repeated with 2.0 mL of 
(2:1 MeCl2: MeOH). Organic extracts were combined, washed with 1.0 mL 0.9% NaCl 
and the solution was dried under N2. The final dried sample was reconstituted with 1.0 
mL TDM (95:5:5 trimethylpentane:MeCl2: MeOH).  Standard curves were based on 
solutions of eicosanol (internal standard), cholesterol ester, cholesterol and triglyceride – 
with initial stock solutions prepared at 1.0 mg/mL in TDM. Standard curves were 
generated by serial dilution of 1mg/mL stock solutions to working concentrations ranging 
from 0.030 – 0.600 mg/mL.  
Ten microliters of liver extract, internal standard, or standard curve samples were 
injected onto an Agilent Series 1100 HPLC system and separated over a 5µ, 100 x 4.6 
mm ID Spherisorb S5W Silica gel column (Waters). The following gradient mobile phase 
was employed to separate lipid species:  Solvent A contained 99:1 Isooctane: 
THF.  Solvent B contained 2:1 Acetone: MeCl2. Solvent C contained 85:15 Isopropanol: 
7.5 mM GlHOAc/7.5 mM ethanolamine in water. The flow rate was a 1.6 mL/min with 
the gradient:  100% solvent A initially, progressing to a mixture of 40:42:18 (solvent A: 
solvent B: solvent C; respectively) over 9.0 minutes. Lipids were detected using a 
SEDEX evaporative light scattering detector (ELSD) with settings of P=1.5 Bar; 
T=32°C; Gain=4.  Each sample was analyzed in duplicate. 
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7.2.7. In vivo studies 
In vivo studies were carried out using both the non-radioisotopic as well as 
radioisotopic methods. For nonradioactive fecal cholesterol transport assay, male C57Bl 
mice Mice (n=8-10 in each group) were used. Typically, mice were teated with the test 
agent for one week followed by collection of feces over 24 h period of time. The feces 
were extracted and cholesterol measured as dscribed in the materials and methods 
section. LXR agonists are frequently used as a tool compound to study reverse 
cholesterol transport in animal models (117,118). Here also a pan LXR agonist, 
T0901317, was used. Groups of male C57Bl mice were treated with T0901317 for 7 
days. At the final day of dosing, plasma, liver, and feces were isolated 2 h post-dose and 
analyzed. RCT studies in apoA-I transgenic, ob/ob, and LDLr-/- were done just like 
C57Bl mice with some modifications as described in the results section. 
Radioisotopic study was done as described (117,196) and shown in figure 7. For 
this assay, J774 cells were grown, treated with acetylated LDL and then 3[H]-cholesterol 
was loaded as drscribed (117,196). First, mice were treated with the test agent for 
indicated time period followed by injection of radioisotopic cholesterol loaded J774 cells 
intraperitonially. After 24 and 48 hours, feces, plasma, and liver, and in some studies bile, 
were isolated. Radioisotoe was counted in all the fractions as drscribed (196). 
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Fig 7.  In vivo macrophage-specific reverse cholesterol transport. In this assay first J774 cells are grown 
in complete medium and then differentiated into macrophages using acetylated LDL followed by 
loading with radioisopic cholesterol (3H-cholesterol). An aliquot of this preparation is counted on 
liquid scintillation counter to determine the volum of macrophage to be administered in each 
mouse. Groups of mice are separately treated with the desired therapeutic agent for 7 days 
followed by intrperitoneal administration of differentiated and 3H-cholesterol loaded macrophages. 
After 24 h of treatment, liver, blood and feces are collected for radioactive counting. 
 
In the Leptin-/- /LDLr-/- double knockout mice, glucose, insulin and 
atherosclerosis were measured as described (132). Cholesterol efflux was measured by 
the method of Smith et al (56). 
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8. RESULTS 
8.1 Regulation of ATP-binding Cassette Transporter A1 (ABCA1) by cyclic-
AMP in Stably Transfected 293 Cells 
 Eukaryotic cells maintain cholesterol homeostasis by regulated cholesterol 
synthesis, uptake, efflux, transport, and removal. Imbalance of any of these regulated 
pathways leads to cholesterol abnormalities and susceptibility to diseases. ATP-binding 
cassette transporter A1 (ABCA1) was identified as the mutant molecule causing a severe 
HDL deficiency syndrome known as Tangier disease (TD) (62-64). These TD patients 
have cholesteryl esters accumulation in tissues, and fibroblasts of these patients are 
unable to facilitate cholesterol and phospholipids efflux, leading to increased 
cardiovascular disease risk. Mice lacking ABCA1 showed similar phenotypes observed 
in TD patients with low levels of HDL (23). Further understanding of the roles of 
ABCA1 in lipid transport and atherosclerosis became clear from studies with ABCA1 
transgenic mice (23). These mice showed enhanced cholesterol efflux from 
macrophages and reduced atherosclerotic lesion formation.  
Regulation of ABCA1 occurs by the transcriptional (111,114) as well post-
transcriptional mechanism (154). cAMP inducible cholesterol efflux to apoA-I in 
macrophages was attributed to the transcriptional up-regulation of the ABCA1. Studies in 
mice confirmed that LXR is an important activator of ABCA1 (23). To understand the 
regulation of ABCA1 protein and mRNA to maintain cellular cholesterol homeostasis 
and requirement of cAMP response element for the cAMP-induced upregulation of the 
ABCA1, a transfected cell line expressing ABCA1 under the control of CMV promoter 
that harbors cAMP response element was used. In this cell line, the cAMP-mediated 
regulation of the ABCA1 gene was studied.  
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cAMP Induces ABCA1 Expression in Transfected 293 Cells 
                        
Fig 8.  Effect of serum on 8-Br-cAMP-induced regulation of ABCA1. The tranasfected cell line was 
incubated in he absence or presence of serum with or without 8-Br-cAMP. 8-Br-cAMP treatment 
was done for 24 h. Cell lysate (25 µg protein) was separated on 8-16% Tris- Glycine gel and 
transferred to nitrocellulose membrane followed by detection with either ABCA1 antibody or a 
polyclonal anti-beta actin antibody. ABCA1 and β-actin proteins bands are shown by arrows.  
ApoA-I-mediated Increased Cholesterol Efflux in Transfected 293 Cells 
                                
Fig 9.  Effect of cAMP on cholesterol efflux in WT 293 cells, and in transfected 293 cells in the presence 
and absence of apoAI and 8-Br-cAMP. The details of the efflux assay are provided in the methods 
section. Dotted bars, 293 cells, shaded bars, 293 cells with 8-Br-cAMP, big dotted bars, 
transfected 293 cells, filled bars, transfected 293 cells with 8-Br-cAMP. 
Since cAMP induces ABCA1 and cholesterol efflux (56,66), the stably 
transfected 293 cells were first examined for their ability to respond to cAMP in inducing 
ABCA1 in culture media containing 1% or 10% serum. As seen in Fig 8, treatment with 
8-Br-cAMP for 24 h showed marked induction of ABCA1 protein in 1% serum 
containing media. However, increasing serum concentration to 10% caused blunted 
induction, showing <50% ABCA1 protein as compared to induction in the presence of 
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1% serum. The stably transfected cells were also examined for requirement of apoA-I as 
cellular cholesterol acceptor. As shown in Fig 9, apoA-I protein is needed as an acceptor 
in the process of ABCA1-mediated cellular cholesterol efflux. 
cAMP Withdrawal Rapidly Diminishes ABCA1 Protein 
           
Fig 10. Effect of 8-Br-cAMP withdrawal on ABCA1 protein levels in the 293 cells stably transfected with 
hABCA1. The transfected cells were treated with or without cAMP for 24 hours, the media was 
removed and cells were further incubated in the same media but without cAMP for 0 h, 2 h, 6h, 
and 24 h as indicated after the + sign. The cell lysates were prepared and ABCA1 and β-actin 
proteins were measured by Western blotting. The respective protein bands of ABCA1 and β-actin 
are indicated by arrows. 
In a separate study, effect of cAMP withdrawal on ABCA1 induction was studied. 
As shown in Fig 10, cells were treated for 24 h with 8-Br-cAMP and then washed with 
media and incubated for various time without 8-Br-cAMP. As shown, ABCA1 protein 
drops to basal level within 6 h of 8-Br-cAMP withdrawal. 
To investigate the effect of 8-Br-cAMP occurs at transcriptional level or 
posttranslational level, cells were harvested at different time points and total mRNA was 
prepared. The concentration of ABCA1 mRNA was quantitated using Q-PCR. The 
results in Fig 11, suggests that 8-Br-cAMP withdrawal reduces ABCA1 mRNA to basal 
level within 6 h, similar to ABCA1 protein. Similar phenomenon was noticed in the 
nontransfected 293 cells (Fig 12), suggesting that transfected cells are behaving just like 
untransfected cells in regulating 8-Br-cAMP-mediated ABCA1 regulation. Measurements 
of cholesterol efflux also showed that within 6 h of 8-Br-cAMP withdrawal, the ABCA1 
function in mediating cholesterol efflux reduces to basal level in stably transfected 293 
Incubation Time (h)      24 + 0              24 + 2            24 + 6             24 + 24 
cAMP       -            +          -          +          -           +         -          + 
ABCA1 
β Actin 
Lanes        1        2       3       4       5        6       7       8 
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cells (Fig 13). These results clearly show that withdrawal of 8-Br-cAMP shuts down 
ABCA1 transcription followed by rapid diminution of ABCA1 protein and cholesterol 
efflux. Thus, 8-Br-cAMP appears to upregulate ABCA1 transcription and does not 
influence ABCA1 protein turn over.  
cAMP Withdrawal Rapidly Diminishes ABCA1 mRNA 
                   
Fig 11. Effect of 8-Br-cAMP withdrawal on ABCA1 mRNA levels in the 293 cells stably transfected with 
hABCA1. Cells were treated with or without 8-Br-cAMP as described in the legends to figure 3, 
and RNA was prepared from the cells. Sixty nanogram of the total RNA were taken for ABCA1 
mRNA quantitation by real-time RT-PCR using Taqman 7900HT. As a control 18S RNA was also 
quantitated. The numbers after the + sign indicates time in h after cAMP treatment. cAMP- 
indicates without cAMP, and cAMP + indicates with cAMP. 
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Diminished Levels of ABCA1 as a Result of cAMP Withdrawal Reduces Chol Efflux 
                      
Fig 12. Effect of 8-Br-cAMP withdrawal on ABCA1 mRNA in the wild type 293 cells. Cells were treated 
with or without 8-Br-cAMP for 24 h, the media was removed and incubated in the media without 
8-Br-cAMP for 2 and 6 h, respectively, as indicated. The numbers after the + sign indicates time 
in h after cAMP treatment. cAMP- indicates without cAMP, and cAMP + indicates with cAMP. 
Diminished Levels of ABCA1 Caused by cAMP Withdrawal Reduces Chol Efflux in 
Transfected Cells 
                             
Fig 13. Effect of cAMP withdrawal on the cholesterol efflux. Stably transfected 293 cells were seeded in 
triplicate in the 24-well plates and cholesterol assay done in the absence and presence of 8-Br-
cAMP as described in the methods section. – indicates without cAMP and + indicates with cyclic 
AMP. The indicated numbers after the + sign in the caption box indicates the time of incubation 
after cAMP treatments. 
 The mechanism of cAMP-induced upregulation of ABCA1 transcription was 
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examined in the presence of PKA inhibitor.  PKA inhibitor blocked the 8-Br-cAMP –
mediated induction of ABCA1 protein (Fig 14). Three PKA inhibitors, as shown in Fig 
15, completely blocked the cAMP-mediated ABCA1 mRNA (Fig 15), suggesting the 
requirement of PKA for the cAMP-mediated transcriptional regulation of ABCA1 gene. 
PKA Inhibitor Blocks cAMP-mediated Induction of ABCA1 
             
Fig 14. Effect of PKA inhibitor on cAMP-induced regulation of ABCA1 in stably transfected 293 cells. 
Stably transfected cells were treated with PKA inhibitor as described in the methods. Cells were 
washed after the treatments and cell lysates were prepared. An aliquot of the cell lysates were 
subjected to SDS-PAGE to detect ABCA1 protein and β-actin protein as an internal standard. 
PKA Inhibitor Blocks cAMP-mediated Induction of ABCA1 mRNA 
                                 
Fig 15. Effect of protein kinase inhibitors on the cAMP-induced ABCA1 mRNA in the stably transfected 
cells. The stably transfected cells were treated with three different protein kinase inhibitors, 
followed by washing and RNA preparation. In each RNA samples, ABCA1 mRNA were 
quantitated. Values shown in the figure are relative to 18S RNA. 
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 Cholesterol efflux was measured to examine if PKA inhibitor blocks cellular 
cholesterol efflux to acceptor apoA-I. As shown in Fig 16, cholesterol efflux also showed 
reduction in the presence of PKA inhibitor, further demonstrating that PKA is required 
for cAMP-mediated induction of ABCA1 and cholesterol efflux. 
PKA Inhibitor Blocks cAMP-mediated Induction of Chol Efflux 
                                
Fig 16. Effect of protein kinase inhibitors on the cholesterol efflux in the 293 cells stably transfected with 
hABCA1. Stably transfected cells were treated with protein kinase inhibitors as indicated and 
cholesterol efflux measured following the method described in the methods section. 
In summary,  the in vitro study with stably transfected 293 cells with ABCA1 
construct showed high levels of ABCA1 expression, and  treatments of ABCA1 
overexpressing cells with cAMP induced expression of ABCA1 mRNA and protein. As 
expected, cAMP-mediated enhanced expression of ABCA1 resulted in increased 
cholesterol efflux. Withdrawal of cAMP caused time-dependent rapid comcomitant 
diminution of ABCA1 protein and mRNA, suggesting transcriptional regulation of 
ABCA1. To gain insights into the cAMP-mediated induction of cholesterol efflux, 
ABCA1 expressing 293 cells were treated with protein kinase inhibitors that abolished 
cAMP-mediated induction of ABCA1 and cholesterol efflux. These results demonstrate 
that cAMP regulates ABCA1 gene expression by transcriptional mechanism and 
continued transcription of ABCA1 is required to maintain cellular level of ABCA1. 
Furhermore, cAMP-mediated upregulation of ABCA1 requires protein kinase-dependent 
mechanism. And finally, overexpressing ABCA1 cells mimics similar cAMP response as 
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with cells having natural ABCA1 promoter.  Thus, the present studies demonstrate that 
the transfected cell line shows similar cAMP-induced regulation of ABCA1 as in the WT 
macrophages, and this effect occurs via PK-mediated pathway. It is also shown that the 
continued transcription of the ABCA1 is required in order to maintain the physiological 
level of intracellular ABCA1, which in turn leads to maintain the intracellular cholesterol 
balance. 
8.2 Optimization of In Vivo Reverse Cholesterol Transport Assay 
8.2.1 Non-radioisotopic Assay 
  As shown in figure 17, treatment with LXR agonist, an ABCA1 inducer, increases 
both LDL and HDL as well as prebeta particles. Quntitation of various liporptoein 
fractions (figure 17 & 18) validated the LXR agonists effect in mice, that is increased 
level of both apoA-I and apoB-containing lipoproteins. LXR agonists are known to have 
lipogenic effects leading to increases in the plasma levels of triglycerides. Indeed, 
triglyceride levels were found to increase in the LXR agonist-treated mice (Figure 18). 
Fecal cholesterol showed increases following T0901317 treatment. A 20 mg/kg/d dose of 
T0901317 showed a robust effect on excretion of cholesterol appearing in the feces 
(Figure 19). 
   
 
Fig 17. Treatment of C57Bl mice with 20 mg/kg/d LXR Agonist, T0901317, increases LDL-C and raises 
HDL-C as measured by FPLC Profile of Plasma from Vehicle- and LXR Agonist Treated Mice. 
Repeat dosing was performed by oral gavage once daily in the morning between 8-9 AM for 7 
days. On the eighth day mice were fasted for 6 h and blood was withdrawn to prepare plasma. 
Results show plasma lipoptoein profile in the vehicle-treated and LXR pan agonist treated mice. 
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Fig 18. Treatment of C57Bl mice with 20 mpk LXR Agonist, T0901317, for 7 days increases LDL-C and 
raises HDL-C and TG, consistent with the effect of LXR agonists on lipoproteins. 
 
 
 
                                  
Fig 19. Fecal Cholesterol in C57Bl Mice Treated with 20 mg/kg/d T0901317. This was a non-
radioisotopic study where radioisotope was not used. Feces were collected 24 h post 7-day 
treatment and subjected to quantitation of cholesterol as described in the methods section. 
 
 To further gain confidence in the measurements of fecal cholesterol following 
treatment with LXR pan agonist, a dose response study was performed.  In this study, 
groups of mice were treated with incrasing dose of LXR agonist (3, 10, and 30 
mg/kg/day), and fecal cholesterol quantitated. As shown in Figure 20, there was a nice 
dose-response seen from 3mg/kg/d to 30mg/kg/d dose range. 
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Fig 20. LXR Agonist T0901317 Increases Fecal Cholesterol in a Dose-dependent Manner. Male C57Bl 
mice were treatd with either vehicle or various concentrations of LXR agonist, T0901317, (3 mpk 
to 30mpk) for 7 days. Feces collected over 24 h were used for cholesterol quantitation. 
 
 Enhancement in the reverse cholesterol transport by LXR agonist occurs via 
ABCA1 and ABCG1 gene induction (197). Therefore, to validate LXR agonist effect, 
ABCA1 and G1 mRNA quantitations were done in the peripheral blood monocytes. As 
shown in Figure 21, a 4-6-fold induction of ABCA1 and G1 was noticed, suggesting that 
LXR agonist induced increases in the fecal cholesterol. 
                                 
Fig 21. LXR Agonist, T0901317 Shows Induction of Target Genes, ABCA1 and G1. Male C57Bl mice 
were treatd with either vehicle or various concentrations of LXR agonist, T0901317, ranging from 
3 mpk to 30mpk for 7 days followed by the collection of blood and preparation of total RNA to 
quantitate ABCA1 and G1 mRNA  
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8.2.2 Radio-isotopic Assay 
Along with non-radioisotopic method of measuring RCT, a radiosiotopic method 
was also carried out. This was done to compare both methods and determine if both 
methods could be used interchangeably depending upon the purpose of a given study. For 
istance, if mRNA profiling is planned in a study, it is better to use non-radioisotope 
method to evaluate RCT and measure gene expression in various tissues. This avoids 
contamination of labwares. A schematic presentation of the macrophage-specific RCT is 
depicted in Figure 7, which is basically a method developed by Dan Rader’s group 
(196,198). 
 
                               
Fig 22. LXR pan agonist, T0901317, shows increases in fecal [3H]-cholesterol counts in macrophage- 
specific Reverse Cholesterol Transport in a Radioisotopic Study. 
 
 Thus, both the non-radioisotopic and radioisotopic methods showed increases in 
the fecal cholesterol following reatment with an ABCA1 inducer, LXR agonist. 
8.3 Effect of ABCA1 Inducers, PPAR-α and LXR Agonists, on RCT in C57Bl 
and ApoA-I Transgenic Mice: Non-radioisotopic Study 
Since both PPAR-α and LXR Agonists have been shown to induce macrophage 
ABCA1 and reverse cholesterol transport (120,199) and action of PPAR-α occurs via 
LXR (200), it was hypothesized that both PPAR-α and LXR agonists should have 
additive/synergistic effect in inducing macrophage specific cholesterol transport. To test 
this hypothesis, C57Bl/6 mice were treated with PPAR-α and LXR agonists separately, 
and also in combination. The results of such study are shown in Figures 23 & 24. As 
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expected, LXR agonist increased total-, HDL-, and LDL-C as well as triglycerides. 
PPAR-α agonist, fenofibrate, on the other hand, showed reductions in HDL-C, LDL-C, 
and triglycerides. The reductions in HDL-C by fenofibrate was a result of rodent-specific 
effect of PPAR-α agonist as described before (133). 
Measurement of fecal cholesterol clarly showed induction of RCT by both PPAR-
α and LXR agonists (Fig 24), both of which have been shown to induce ABCA1 
(120,201). A combination of PPAR-α and LXR agonists showed massive increase in the 
fecal cholesterol excretion (Fig 24), suggesting a synergistic effect and confirming the 
results of Nakaya et al (200) that PPAR-α requires LXR to nduce macrophage reverse 
cholesterol transport. 
                             
Fig 23. Plasma Lipids in LXR, PPAR-α, and Combination of LXR and PPAR-α Treated C57Bl Mice. 
 
                                    
Fig 24. PPAR-α and LXR Agonist Enhance RCT in C57Bl Mice as Measured by Nonradioisotopic Assay. 
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 ApoA-I transgenic mice show increased levels of HDL-C (202) and expression of 
apoA-I in apoE-deficient mice attenuates atherosclerotic lesion formation (43). Since 
overexpression of apoA-I promotes reverse cholesterol transport from macrophage to 
feces (196), it is possible that the antiatherosclerotic efficacy of PPAR-α and LXR 
agonists (131) occur via enhanced reverse cholesterol transport.  
The two ABCA1 inducers, PPAR-α and LXR agonists, were also tested in apoA-I 
transgenic mice for their efficacy in promoting reverse cholesterol transport. As shown in 
figures 25 and 26, treatment of apoA-I transgenic mice with ABCA1 inducers, fenofibrte 
and T0901317, further increased plasma levels of HDL. A combination of PPAR-α and 
LXR agonist (Feno + T1317) showed improved lipid profile when compared to vehicle 
treated group. Because mouse is an HDL animal transporting majority of their cholesterol 
as HDL partcles and, unlike humans, non-HDL cholesterol is only a fraction of the total 
cholesterol, expressing apoA-I in HDL increases HDL-C further, but not in the 
proportion of plasma levels of apoA-I. HDL increases only to certain level as evidenced 
by combined treatment of apoA-I transgenic mice with two HDL elevators, PPAR-α and 
LXR agonists (Fig. 25 & 26). 
 
                        
Fig 25. Plasma Lipoprotein Profile in LXR, PPAR-α, and Combination of LXR and PPAR-α Treated ApoAI-Tg 
Mice 
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Fig 26. Plasma Lipids in LXR, PPAR-α, and Combination of LXR and PPAR-α Treated ApoAI-Tg Mice. 
The apoA-I transgenic mouse used in the present study has been described elsewhere (202). 
 
  Measurements of fecal cholesterol further demonstrated that expression of apoA-I 
in apoA-I transgenic mice increase reverse cholesterol transport as seen with increases in 
fecal cholesterol (Fig 27). Both PPAR-α and LXR agonists showed similar efficacy in 
terms of fecal cholesterol excretion. Again, the combinationof PPAR-α and LXR agonists 
show synergistic effects on fecal cholesterol excretion 
 
             ApoA-I Transgenic Mice 
 
                                    
Fig 27. PPAR-α and LXR Agonists Enhance RCT in ApoA-I-tg Mice in Nonradioisotopic Study. Fecal 
cholesterol was collected and cholesterol measured as described in the materials and methods 
section. 
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8.4 Effect of PPAR-α and LXR Agonists on RCT in C57Bl Mice: Radioisotopic 
Study 
Fecal cholesterol excretion was further verified by doing a radioisotopic assay in 
which 3[H]-cholesterol was loaded to J774 cells, injected intraperitoneally and 
radioisotope followed in the feces over 24 h time. As shown in Fig 28, the radioisotope 
assay corroborated non-radioisotope assay (Fig 27) in terms of synergistic effects of 
PPAR-α and LXR agonists in promoting macrophage cholesterol excretion through the 
feces. 
                      
Fig 28. PPAR-α and LXR Agonists Enhance RCT in C57Bl Mice as Measured by Radioisotopic Assay. 
The details of experiment and fecal cholesterol isolation and determination of fecal radioisotope 
counts are described in the materials and methods section. 
 
8.5 Effect of Antiatherosclerotic Agents on Reverse Cholesterol Transport in 
Hyperlipidemic Animal Models 
Hyperlipidemic mouse models like ob/oblep/lep (leptin-deficient) and LDLr-/- 
(LDLr-deficient) mice are used for studying pathophysiology of diabetes and 
atherosclerosis, respectively (132). These mouse models have also been used to evaluate 
efficacy of hypolipidemic agents (203). Although several agents show attenuation of 
atherosclerotic lesion in LDLr -/- mice, it is not known if this ccurs exclusively in an 
LDL-driven mechanism or RCT also plays a role. As shown in Figure 29, both PPAR-α 
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(GW9578) and LXR (T0901317) agonists show cholesterol mobilization in LDLr -/- mice 
as shown by plasma 3H counts. Fecal counts also showed increases; LXR agonist, 
T0901317, showing greater enhancement in RCT compared to PPAR-α agonist, 
GW9578. 
    
Fig. 29.Mobilization of administered radioisotopic cholesterol as macrophages in LDLr -/- mice by LXR 
and PPAR-α agonists, T0901317 and GW9578, respectively. Mice were treated with these 
agonists as indicated for 7 days followed by administration of radioisotopic cholesterol loaded 
macrophages via intraperotoneal injection. Mice were sacrificed 24 h post macrophage 
administration and blood, liver and feces were collected for radioactive counting. 
   
A non-isotopic RCT was perfromd in ob/ob mice. These mice are hyperglycemic 
and hyperinsulinemic. Treatements with PPAR-α agonist (GW9578), PPAR-γ agonist 
(rosiglitazone) LXR agonists (GW3965, T01317) or a combination of both PPAR-α and 
LXR agonists (GW3965 + T01317) showed induction of RCT pathway leading to 
excretion of cholesterol in the feces. As shown in figure 30, rosiglitazone did not enhance 
RCT in this model, whereas, both PPAR-α and LXR agonists showed marked increased 
in RCT, measured as fecal cholesterol. Two combinations of PPAR-α and LXR agonists, 
one less potent (GW3965) and one more potent (T01317) were evaluated in this model. 
While PPAR-α and LXR agonists show with less potent as well as with more potent LXR 
agonists.  
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Fig 30. Fecal cholesterol excretion in ob/ob mice treated with PPAR-α agonist (GW3965), PPAR-γ 
agonist (rosiglitazone), LXR agonists (GW9578 & T01317), and a combination of PPAR- and 
LXR agonists (GW9578 + T01317). All procedures were done as described in Figure 29 except 
the administration of radioisotpic cholesterol loaded macrophages. In this assay only the feces 
were collected for cholesterol quantitation using LC-MS. 
   
8.6 Inflammation and Reverse Cholesterol Transport 
8.6.1 In vitro Study: TNF- α-mediated apoA-I Regulation 
An inverse correlation has been noticed between proinflammatory cytokines, and 
reverse cholesterol transport (204) and inflammation impairs reverse cholesterol transport 
in animal models (185) and in humans (205). Several studies have reported inflammation 
leading to low levels of apoA-I and HDL-C. Indeed, administration of apoA-I attenuates 
LPS-induced endotoxemia (206). A direct correlation of TNF-α-induced lowering of 
apoA-I was demonstrated (207-209). We looked into the molecular mechanism of apoA-I 
down-regulation by proinflammatory cytokine, TNF-α. First, we examined if TNF-α 
lowers apoA-I mRNA in cell model of hepatocytes, HepG2 cell. As seen in Figures 31 
and 32, TNF-α dowregulates apoA-I protein and mRNA, respectively. TNF-α was found 
to decrease apoA-I in the spent media by about 50% (Fig 31). ApoA-I mRNA also 
showed a reduction of 50% following treatment with TNF-α. 
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Fig 31. HepG2 cells, a model of human hepatocytes, were treated with agents as described in the figure. 
As controls, both inducers and repressors of apoA-I were used as tool agents. As shown, TNF-α 
reduced apoA-I protein in the media. 
 
                              
Fig 32. HepG2 cells were grown in culture as described in the legends to Fig 31. Cells were harvested to 
prepare total RNA and apoA-I mRNA quantitated by RNAse protection assay. 
 
8.6.2 In vivo Study: LPS-induced Inflammation and Cholesterol Efflux 
To corroborate cell-based assay, in vivo studies were carried out to examine 
levels of apoA-I and HDL-C in mice previously treated with LPS and compared with 
sham-treated group of mice. As shown in Fig 33, LPS treatmentshowed marked increases 
in the VLDL peak and significant reductions in HDL peak, suggesting that LPS-induced 
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increases in the proinflammatory cytokines resulted in a proatherogenic lipid profile with 
2-fold increases in apoB-lipoproteins and significant reductions in apoA-I particles (Fig 
34). 
                                             
                             
Fig 33. FPLC profile of plasma isolated from control and LPS-treated mice. Blue trinagles represent 
control and red circles indicate FPLC-treated group. Mice were treated with LPS (5 µg/kg/day) 
followed by blood withdrawal and lipoprotein profile analysis. As shown, LPS treatment markedly 
increased triglycerides-rich lipoprotein particles and lowered apoA-I containing lipoproteins. 
 
 
                                 
Fig 34. Fractions obtained in the FPLC profile (shown in Fig 33) were collected and peaks corresponding 
to non-HDL and HDL fractions were pooled and cholesterol concentration quantitated. Blue bars 
represent control and red bars represent LPS-treated mice. 
  To examine if increased levels of proinflammatory cytokines as a result of LPS 
treatment leads to impaired reverse cholesterol transport, plasma obtained from control 
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and LPS-treated mice were apoB-depleted and cholesterol efflux measured as described 
in Section 7.2.2. As seen in figure 35, cholesterol efflux capability was found to be 
compromised in the LPS-treated mice when compared to the control mice, suggesting 
that cholesterol efflux capability of plasma is impaired in proinflammatory state. Further 
evaluation of impaired cholesterol efflux in LPS-treated mice was done by measuring 
fecal cholesterol counts in macrophage-reverse choletserol transport in radioisotopic 
assay. As seen in figure 36, both plasma and fecal counts decreased, suggesting impaired 
reverse cholesterol transport. 
                                    
Fig 35 Cholesterol efflux in apoB-depleted plasma. As shown increasing concentration of acceptor apoA-
I was used in the media. Blue line represents control and red line represents LPS-treated group. 
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Fig 36. Macrophage-specific reverse cholesterol transport in mice treated with LPS. Groups of mice were 
either sham-treated or LPS treated and injected IP with activated macrophages induced by ac-LDL 
and loaded with radioisotopic cholesterol. After 48 h, plasma and feces were isolated and 
radioactive counts were measured. Blue bars represent control and red bars represent LPS-treated. 
8.7 HDL Functionality in Animal Model of Hyperlipidemia, Diabetes, Low-grade 
Inflammation and Atherosclerosis 
Since inflammation impaires cholesterol efflux and reverse cholesterol transport, 
a process needed to remove atherogenic cholesterol accumulation in the peripheral 
tissues, including macrophages entrapped in the subendothelial space, it was 
hypothesized that disease conditions that leads to oxidative stress and inflammation may 
increase arterial atherosclerosis burden. Hyperlipidemia and diabetes mellitus are such 
disease conditions in which increased cholesterol, free fatty acids, glycated end products, 
and MPO, lead to inflammation and oxidative stress. To test this hypothesis, a double 
knockout mouse was generated by crossing hyperlipidemic LDLr-deficient mouse with 
leptin-deficient (ob/ob) hyperglycemic diabetic mouse. These mice were screened for 
insulin, hyperglycemia and hyperlipidemia. Feeding hyperlipidemic diet for 10 weeks 
makes them severely hyperlipidemic, hyperglycemic, and hyperinsulinemic. These 
profiles are highly atherogenic and lead to aortic lipid deposition and lesion formation. 
After feeding hyperlipidemic Western Diet for 10 weeks, mice were treated for 6 weeks 
with LXR agonist, T0901317, a reference agent known to show anti-inflammatory and 
antiatherosclerotic activities. Another reference agent, metformin, was used as an 
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antidiabetic agent (210,211). As shown, these mice show high TG and cholesterol levels 
(Fig 37, upper 2 panels) and also increased levels of glucose and insulin (Fig 37, lower 
two panels) as compared to LDLr-deficient or ob/ob mouse (compare blue and orange 
bars with green bar in the vehicle-tretaed group only).  
Treatment of the double knockout mice (DKO) with anti-inflammatory agent 
LXR agonist, T0901317, known to inhibit progression of atherosclerosis (131), with 
AMPK activator, metformin, known to have antidiabetic effect (203), and a combination 
(COMB) of metformin, quercetin (212), and curcumin (213), which are anti-
inflammatory agents. Both quercetin and curcumin show antiatherosclerotic activity as 
well (214-216) showed improvements in lipid and glycemic profile. As seen in Figure 37, 
treatment with COMB reduced total cholesterol, triglycerides, glucose and insulin more 
than T1317 (used as a reference) and metformin alone. 
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Fig 37. Lipid, glucose and insulin levels in ob/ob (blue), LDLr KO (orange) and ob.ob/LDLr DKO (green) 
mice. Animals were fed WD for 10 weeks followed by 6 weeks treatment with LXR agonist, 
T0901317 (20 mg/kg/day, qd) Metformin (300 mg/kg/day, bid), and COMB (Met, 300 mg/d/kg; 
quercetin 200 mg/d/kg.Curcumin 400 mg/d/kg, bid). * p<0.025 compared to Vehicle control. 
To examine effect of COMB on attenuation of inflammation, proinflammatory 
cytokines and haptoglobin were quantitated. Haptogobin is an acute phase protein (217), 
synthesized primarily in the liver (218), and associates with HDL (219). Humans with 
cardiovascular disease have increased levels of haptoglobin (220-222), and anti-
inflammatory activity of HDL isolated from mice lacking haptoglobin is compromised 
(219). COMB reduced proinflammatory cytokines IL-6 and TNF-α, adhesion molecule 
VCAM1, and haptoglobin (Fig 38).  
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Fig 38. Animals were fed WD for 10 weeks followed by 6 weeks treatment with LXR agonist, T0901317 
(20 mg/kg/day, qd) Metformin (300 mg/kg/day, bid), and COMB (Met, 300 mg/d/kg; quercetin 
200 mg/d/kg; Curcumin 400 mg/d/kg, bid). * p<0.025 compared to Vehicle control. 
Proinflammatory cytokines and haptoglobin were measured in the plasma 
We hypothesized that attenuation of hyperlipidemia and hyperglycemia-induced 
proinflammatory cytokines, and hyperglycemia in DKO would result into dampening of 
HDL function through impairement of cholesterol efflux. We therefore, measured both 
cholesterol efflux in the apoB-depleted plasma and in a separate experiment carried out 
macrophage-specific reverse cholesterol transport using radioisotopic assay. The results 
of these studies are shown in Figure 39.  Attenuation of cholesterol efflux (Fig 39, Left 
Panel) as well as increases in fecal cholesterol as a result of enhanced RCT following 
treatments with COMB, were observed (Fig 39, Right Panel). 
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Fig 39. Animals were fed WD for 10 weeks followed by 6 weeks treatment as shown in the legend to Fig 
38. * p<0.025 compared to Vehicle control. For serum chol efflux, serum wasapoB-depleted and 
cholesterol efflux measured. For MS-RCT, radioisotopic assay was performed. 
                      
Fig 40. Animals were fed WD for 10 weeks followed by 6 weeks treatment with LXR agonist, T0901317 
(20 mg/kg/day, qd) Metformin (300 mg/kg/day, bid), and COMB (Met, 300 mg/d/kg; quercetin 
200 mg/d/kg; Curcumin 400 mg/d/kg, bid). * p<0.025 compared to Vehicle control. At the time of 
necropsy, aliquot of plasma from each muse from each group was pooled and HDL isolated, 
protein content determined, and used for assay.  
A portion of the plasma was used to isolate HDL fraction to evaluate anti-
inflammatory activity by measuring VCAM1 in TNF-α-induced human aortic endothelial 
cells (HAEC). As shown in Figure 40, TNF-α showed induction of VCAM1 as compared 
to cells with no treatment with TNF-α. In the presence of HDL isolated from treated 
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groups, a clear anti-inflammatory activity was noticed in all groups, but attenuation of 
TNF-α-induced inflammation was greater in the COMB group as compared to other two 
treatment groups. 
 
              
Fig 41. Oil-Red O stained aorta (Left) and sections of aortic sinus (right) of COMB and control group. 
             
Fig 42. Oil-Red O stained area shown in Figure 41 was measured and plotted. 
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 To examine the effect of HDL function attenuation on atherosclerotic lesion area, 
aorta was isolated from each mouse from all groups and lesion area quantitated by Oil-
Red O staining. Additionally, aortic sinus sectioning was done and stained with Oil-Red 
O. Greater effects on reducing lesion area was seen in COMB as compared to other two 
groups (Figs. 41, 42). The anti-inflammatory activity of HDL, cholesterol efflux 
capability, and lipid profile, all correlated with the extent of lesion formation. COMB 
showed greater reductions in lipids, glucose and proinflammatory cytokines and at the 
same time showed increased cholesterol efflux together with enhanced macrophage-
specific reverse cholesterol transport. 
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9. DISCUSSION 
The primary objective of this dissertation was to have an in-depth understanding 
of HDL functionality and how it leads to modulation of reverse cholesterol transport and 
eventually aortic lipid deposition in pathophysiological conditions of hyperlipidemia, 
diabetes, and inflammation. Given the higher prevalence of cardiovascular morbidity and 
mortality in diabetics, it is important to understand if HDL dysfunction is one of the 
factors causing arterial lipid deposition in diabetics. Recent cell-based studies do suggest 
a link between HDL and glucose metabolism through both insulin-dependent (137,138) 
and –independent mechanisms (139). Indeed, HDL has been shown to modulate glucose 
metabolism in type 2 diabetic patients (161), and infusion studies with recombinant and 
reconstituted HDL (rHDL) demonstrated attenuation of coronary plaque morphology and 
volume (47,141,223) through enhanced RCT and improved endothelial function in type 2 
diabetes mellitus (142).  
The two major components of the HDL-mediated RCT are apoA-I, the main 
protein constituent of HDL particles, and a membrane protein, ABCA1, that facilitates 
the cellular cholesterol efflux across cell membrane to the acceptor nascent lipid-poor 
apoA-I, a preferred acceptor of ABCA1-mediated lipid efflux. Since apoA-I has been 
shown to specifically bind to ABCA1 (66), the lipid-poor apoA1 (preβ-HDL) functions 
as an acceptor of cholesterol and phospholipid in an ABCA1-dependent manner resulting 
the formation of mature cholesterol ester rich spherical α-HDL particles. Thus, a 
functional apoA-I is important in the process of RCT. A modified apoA-I as a result of 
oxidative damage may lead to dysfunctional HDL (189,191). Indeed, oxidatively 
modified dysfunctional apoA-I has been identified in human atherosclerotic plaques 
(152). The importance of apoA-I and ABCA1 in reverse cholesterol transport has been 
thoroughly studied and demonstrated in knockout and transgenic mouse models (42,224). 
ApoA-I KO mice have very low levels of HDL and are susceptible to develop 
atherosclerosis (42) while apoA-I transgenic mice show resistant to atherosclerosis (224). 
Overexpression of ABCA1 increased plasma levels of HDL and increased apoA-I-
mediated cholesterol efflux from macrophages (78). The data from two different groups 
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(77,78) are in agreement with regard to the elevated levels of HDL, cholesterol efflux and 
inhibition of atherogenesis in ABCA1 transgenic mice (22), and in A1-CIII-AIV 
transgenic mice (83). Similarly, Abca1-deficient mice were severely hypolipidemic with 
almost complete absence of HDL, a condition observed in TD (62). Thus, modulation of 
ABCA1 is an important factor in the overall reverse cholesterol transport in the process 
of cholesterol removal from the peripheral tissues and arterial wall. ABCA1 regulation is 
of utmost importance in driving the RCT and sparing cells from toxicity arising from 
intracellular cholesterol accumulation.  
In a series of studies carried out in ABCA1 overexpressing cell line, it is 
demonstrated that ABCA1 regulation is highly controlled at the transcriptional level, 
since upregulation of ABCA1 increased ABCA1 protein in the same proportion as the 
mRNA, and withdrawal of ABCA1 transcription inducer resulted in proportional 
reductions in both the mRNA and protein. Further studies showed that transcriptional 
regulation of ABCA1 was dependent on a phosphorylation step. Thus, ABCA1 regulation 
is tightly regulated at the transcriptional level where intracellular cholesterol serves as a 
sensor to turn cholesterol efflux on and off in order to maintain adequate intracellular 
cholesterol for cellular needs. Studies in RAW264.7 macrophages identified CRE-
responsive element, and detected a phosphorylated CRE (110). They also identified in 
RAW264.7 cells a STAT3/4 site near the b’CRE, which appeared to be required for 
cAMP-mediated activation of ABCA1 transcription. The present study further extends 
the understanding of cellular ABCA1 regulation and identifies PKA as a player in the 
phosphorylation of CRE. Present study also demonstrates, in a non-macrophage cell line, 
that CMV promoter-mediated transcription of ABCA1 possibly does not require a 
STAT3/4 site, and that transcription and translation are tightly regulated and linked to the 
level of cellular ABCA1 protein in a non-macrophage cell line. While ABCA1 
phosphorylation was noted in the cAMP-induced cholesterol efflux (108), a direct 
correlation between inhibition of phosphorylation and ABCA1 transcription is 
demonstrated in the present study. 
In optimized non-radioisotopic and radioisotopic assays, a number of agents 
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known to modulate lipid metabolism and reverse cholesterol transport were evaluated. 
ApoA-I functions as an acceptor of cellular cholesterol in ABCA1-mediated pathways 
and plays an important role in RCT. ApoA-I transgenic mice show increased levels of 
HDL-C (202) and expression of apoA-I in apoE-deficient mice attenuates atherosclerotic 
lesion formation (43). Results presented demonstrate that overexpression of apoA-I 
enhances reverse cholesterol transport, consistent with the role of apoA-I in promoting 
reverse cholesterol transport from macrophage to feces (196). By the same mechanism, it 
is possible that the antiatherosclerotic efficacy of PPAR-α and LXR agonists (131) occur 
via enhanced reverse cholesterol transport, since both of these agents increase apoA-I and 
HDL. LXR pan agonist, T0901317, known to up-regulate ABCA1 & G1 gene expression 
showed a nice dose-dependent increase in the fecal cholesterol which was associated with 
increases in HDL and monocytic ABCA1 mRNA, consistent with the notion that ABCA1 
facilitates excretion of cholesterol through RCT.  An interesting observation made in the 
present study was the synergistic effect of LXR and PPAR-α in inducing fecal cholesterol 
excretion. Given the requirement of LXR for the PPAR-α -mediated enhancement in 
RCT (200), it is understandable why a synergistic effect was noticed in mice treated with 
PPAR-α and LXR agonists simultaneously. 
The ATP-binding cassette transporter A1 (ABCA1), an important player in the 
cholesterol efflux that mediates transfer of intracellular cholesterol to lipid-poor HDL as 
an acceptor, has been shown to modulate insulin secretion (138). HDL reverses the 
deleterious effects of oxidized low-density lipoprotein (LDL) on insulin secretion by 
pancreatic beta cells (137). Additionally, it is suggested that HDL and its major 
apolipoprotein, apoA-I, activate the key metabolic regulatory enzyme, AMP-activated 
protein kinase (AMPK), in endothelial cells and are critical for the nitric oxide–mediated 
vasodilatory effects of HDL (140). Indeed, activation of AMPK induces cholesterol 
efflux from macrophage-derived foam cells leading to reductions in lesion burden in 
apoE-deficient mice (225). Taken together, it appears that AMPK activators may not only 
have benefits from its antidiabetic effect, but also may impart additional beneficial effects 
through influencing RCT. Therefore, a double knock mouse was produced that exhibits 
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characteristics of hyperlipidemia, hyperglycemia, low-grade inflammation, and develop 
atherosclerotic lesion on hyperlipidemic diet. Studies performed in this mouse model 
with an anti-inflammatory agent, T0901317, an AMPK activator, metformin, and a 
combination of anti-inflammatory agent and AMPK activator clearly suggest that 
attenuation of hyperglycemia, insulin resistance, hyperlipidemia and low-grade 
inflammation improves HDL functionality as measured by cholesterol efflux and 
macrophage-specific reverse cholesterol transport. This improvement in HDL 
functionality translated into attenuation of aortic lipid deposition as measured by lipid 
staining. These data clearly demonstrate that improvement in HDL functionality may 
benefit diabetic patients who have elevated oxidative stress and inflammation with 
compromised HDL function (182). 
Poor glycemic control in type-1 diabetes is associated with accelerated oxidative 
damage to apolipoprotein (apo) A-I, the main protein component of HDL (150) and 
advanced glycated albumin diminishes anti-inflammatory properties of HDL (179,180). 
Reconstituted HDL shows anti-inflammatory activity in humans (164,168,181). ABCA1-
mediated cholesterol efflux capability of HDL is compromised in type 2 diabetes patients 
(182), possibly as a result of oxidative damage to apoA-I (183). Since antioxidative and 
antiinflammatory properties of HDL are impaired in diabetics (184), oxidative stress and 
inflammation may contribute to HDL dysfunction (185). HDL undergoes modification 
and multiple structural changes in an inflammatory condition and transforms normal 
functional HDL into “acute phase HDL”, enriched in free fatty acids, triglycerides, serum 
amyloid A (SAA), and decreased anti-inflammatory enzymes, including paraoxanase 1 
(186,187). One such acute phase protein is haptoglobin (217). This protein is synthesized 
primarily in the liver (218) and secreted in the circulation where it associates with HDL 
(219). In humans, increased levels of haptoglobin are associated with cardiovascular 
disease (220-222). HDL isolated from mice lacking haptoglobin show anti-inflammatory 
activity compared to WT mice (219), suggesting a proinflammatory role of haptoglobin. 
In the present study, treatment of DKO mice with COMB lowered haptoglobin 
concentration in the blood, and possibly contributed to attenuation of HDL functionality 
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as measured by cholesterol efflux. In addition, inflammation induces secretion of 
myeloperoxidase (MPO), which has been shown to modify apolipoprotein A-I (apoAI) 
and impair its ability to accept cholesterol (151,188-191). MPO-mediated oxidation of 
apoA-I makes it proinflammatory (192). Tryptophan substitution with phenylalanine in 
apoA-I renders it resistance to MPO oxidation (193). All these studies suggest that the 
fundamental changes due to lipid and carbohydrate dysregulation together with increase 
in inflammation in diabetes mellitus leads to HDL dysfunction. 
The present study demonstrates that apoA-I and ABCA-I are important players in 
the RCT, and attenuation of oxidative stress, inflammation, and lowering of liplid and 
glucose, restores HDL function, and exert beneficial effect in the process of lipid removal 
from lipid-laden macrophage in the arterial wall.  
 
 
Fig 43. Working hypothesis showing factors causing HDL dysfunction leading to arterial lipid deposition 
and restoration of HDL dysfunction following treatment with hypolipidemic, anti-inflammatory, 
and antidiabetic agents, termed as COMB. As shown, in normal physiological conditions, HDL 
carried out its function of cholesterol efflux in the arterial wall and inhibits accumulation of lipids. 
In pathophysiological conditions where oxidative stress and inflammation are elevated, HDL 
undergoes modifications. The functions of modified HDL are compromised leading to dampened 
cholesterol efflux capability. Agents that attenuate inflammation, hyperglycemia, and oxidative 
stress improve HDL functionality and restores cholesterol effluc capability leading to reductions 
in arterial lipids. 
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As a working hypothesis, the biologic sequence of events that leads to HDL 
dysfunction is shown in figure 43. HDL performs its normal function by removing 
cholesterol from lipid-laden macrophages in the arterial wall, thus causing lesion 
regression. The inflamed macrophages entrapped in the subendothelial space secrete 
proinflammatory cytokines and haptoglobin, and activates wnt signaling through LRP5/6 
as a result of uptake of aggregated LDL (226) in hyperlipidemic conditions. Wnt/β-
catanin signaling has been shown to induce proliferation of vascular smooth muscle cells 
(227), which may lead to narrowing of artery lumen and eventually causing occlusion. 
High oxidative stress, diabetes, and inflammation cause dysfunctional HDL, leading to 
dampening of cholesterol efflux capability and impaired arterial cholesterol removal. 
Treatment with COMB attenuates hyperlipidemia, oxidative stress and inflammation, 
which lead to improvement of HDL function and removal of cholesterol from lipid-
ladden macrophages entrapped in the sub-endothelial space.  
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